

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083673 A1(51) International Patent Classification⁷: C07D 471/10, A61K 31/435(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/10736

(22) International Filing Date: 5 April 2002 (05.04.2002)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
60/282,722 10 April 2001 (10.04.2001) US(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL,
INC. [US/US]; U.S. Route #202, Raritan, NJ 08869-0602
(US).(72) Inventors: JORDAN,, Alfonzo; 329 Regency Drive,
North Wales, PA 19454 (US). PAN, Kevin; 409 Greene
Lane, Phoenixville, PA 19460 (US). REITZ, Allen, B.; 109
Greenbriar Road, Lansdale, PA 19446 (US).(74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, NJ 08933
(US).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS



(57) Abstract: The present invention is directed to novel 1,3,8-triaza-spiro[4.5]decan-4-one derivatives of general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

WO 02/083673 A1

1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE
TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS

5

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from United States provisional application Serial No. 60/282,722, filed April 10, 2001, the contents of which are hereby incorporated by reference.

10 The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, 15 migraine, asthma, cough and for improved cognition.

BACKGROUND OF THE INVENTION

The ORL-1 (orphan opioid receptor) G-protein coupled receptor, also known as the nociceptin receptor, was first reported in 1994, and was discovered based on its homology with the classic delta-, mu-, and kappa-opioid receptors. The ORL-1 G-protein coupled receptor does not bind opioid ligands with high affinity. The amino acid sequence of ORL-1 is 47% identical to the opioid receptors overall, and 64% identical in the transmembrane 25 domains. (*Nature*, 1995, 377, 532.)

The endogenous ligand of ORL-1, known as nociceptin, a highly basic 17 amino acid peptide, was isolated from tissue extracts in 1995. It was named both nociceptin, because it increased sensitivity to pain when injected 30 into mouse brain, and orphanin FQ (OFQ) because of the terminal phenylalanine (F) and glutamine (Q) residues that flank the peptide on either side. (WO97/07212)

Nociceptin binding to ORL-1 receptors causes inhibition of cAMP synthesis, inhibition of voltage-gated calcium channels, and activation of potassium conductance. In vivo, nociceptin produces a variety of pharmacological effects that at times oppose those of the opioids, including 5 hyperalgesia and inhibition of morphine-induced analgesia. Mutant mice lacking nociceptin receptors show better performance in learning and memory tasks. These mutant mice also have normal responses to painful stimuli.

The ORL-1 receptor is widely distributed / expressed throughout the 10 human body, including in the brain and spinal cord. In the spinal cord, the ORL-1 receptor exists in both the dorsal and ventral horns, and precursor mRNA has been found in the superficial lamina of the dorsal horn, where primary afferent fibers of nociceptors terminate. Therefore, the ORL-1 has an important role in nociception transmission in the spinal cord. This was 15 confirmed in recent studies wherein nociceptin, when given to mice by i.c.v. injection, induced hyperalgesia and decreased locomotor activity. (*Brit. J. Pharmacol.* 2000, 129, 1261.)

Adam, et al., in U.S. Patent No. 6,071,925 (and in EP 0856514) disclose 20 1,3,8-triazaspiro[4,5]decan-4-one derivatives, agonists and/or antagonists of the OFQ receptor. More recently, Higgins, et.al., in European Forum of Neuroscience 2000, Brighton, U.K., June 24-28, 2000, Poster 077.22 disclosed, 8-[(1*R*,3*a*S)-2,3,3*a*,4,5,6-hexahydro-1*H*-phenalen-1-yl]-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one useful as a cognition enhancers. Adam et 25 al., in EP 921125-A1 disclose 1,3,8-triazaspiro[4.5]decan-4-one derivatives, agonists and / or antagonists of the OFQ receptor.

Ito, et al., in EP 0997464 disclose 1,3,8-triazaspiro[4.5]decan-4-one compounds as ORL-1 receptor agonists.

30

Watson, et al., in WO 99/59997 disclose 1,3,8-triazaspiro[4.5]decan-4-ones with high affinity for opioid receptor subtypes, useful for the treatment of


migraine, type II diabetes, sepsis, inflammation, incontinence and/or vasomotor disturbance.

JP2000169476, assigned to Banyu Pharmaceutical Co., Ltd, disclose 4-5 oxoimidazolidine-5-spiro-nitrogen containing heterocyclic compounds which inhibit binding of nociceptin to the ORL1 receptor.

We now describe novel small molecule modulators of the ORL-1 receptor, useful for the treatment of disorders and conditions mediated by the 10 ORL-1 receptor, such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

SUMMARY OF THE INVENTION

15 The present invention is directed to compounds of the general formula
(I)



wherein

R¹ is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl and
20 aralkyl;

wherein the aryl or aralkyl group is optionally substituted with one to four substituents independently selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋

$\text{C}_1\text{-}\text{C}_6$ alkylsulfonyl, amido, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amido, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amido, sulfonyl, aminosulfonyl, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ aminosulfonyl, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ aminosulfonyl or $\text{C}_3\text{-cycloalky}$;

R^2 is selected from the group consisting of hydrogen, $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, $\text{C}_2\text{-}\text{C}_6\text{alkenyl}$, $\text{C}_{2\text{-}6}\text{alkynyl}$, hydroxyamino $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, aminocarbonyl $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, $\text{C}_1\text{-}\text{C}_6\text{alkoxycarbonylC}_1\text{-}\text{C}_6\text{alkyl}$, aryl, $\text{C}_3\text{-}\text{C}_8\text{cycloalkyl}$, partially unsaturated carbocyclyl, heteroaryl, heterocycloalkyl, $\text{C}_1\text{-}\text{C}_6\text{aralkyl}$, carbocyclyl $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, heteroaryl $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, heterocycloalkyl $\text{C}_1\text{-}\text{C}_6\text{alkyl}$ and phthalimidoyl $\text{C}_1\text{-}\text{C}_6\text{alkyl}$;

wherein the alkyl group is optionally substituted with one to two substituents independently selected from hydroxy, carboxy, cyano, amino, $\text{C}_1\text{-}\text{C}_6\text{alkylamino}$, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amino, hydroxy $\text{C}_1\text{-}\text{C}_6\text{alkylamino}$, amino $\text{C}_1\text{-}\text{C}_6\text{alkylamino}$, $\text{C}_1\text{-}\text{C}_6\text{alkylaminoC}_1\text{-}\text{C}_6\text{alkylamino}$ or di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amino $\text{C}_1\text{-}\text{C}_6\text{alkylamino}$,

wherein the aryl, cycloalkyl, carbocyclyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently selected from halogen, $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, halogenated $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, $\text{C}_1\text{-}\text{C}_6\text{alkoxy}$, nitro, amino, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amino, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amino, $\text{C}_1\text{-}\text{C}_6\text{alkylsulfonyl}$, amido, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amido, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amido, sulfonyl, aminosulfonyl, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ aminosulfonyl, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ aminosulfonyl or $\text{C}_1\text{-}\text{C}_4\text{alkoxycarbonyl}$;

a is an integer from 0 to 2;

R^3 is selected from the group consisting of $\text{C}_1\text{-}\text{C}_4\text{alkyl}$ and hydroxy $\text{C}_1\text{-}\text{C}_4\text{alkyl}$;

n is an integer from 0 to 1;

X is selected from the group consisting of $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, $\text{C}_{2\text{-}6}\text{alkenyl}$, $\text{C}_{2\text{-}4}\text{alkyl-O}$ and $\text{C}_{2\text{-}4}\text{alkyl-S}$;

wherein the alkyl group is optionally substituted with one to two substituents independently selected from fluoro, $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, fluorinated $\text{C}_1\text{-}\text{C}_6\text{alkyl}$, $\text{C}_1\text{-}\text{C}_6\text{alkoxy}$, nitro, amino, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amino, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amino, $\text{C}_1\text{-}\text{C}_6\text{alkylsulfonyl}$, amido, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amido, di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ amido, sulfonyl, aminosulfonyl, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ aminosulfonyl or di $(\text{C}_1\text{-}\text{C}_6\text{alkyl})$ aminosulfonyl;

and wherein X is $\text{C}_{2\text{-}4}\text{alkyl-O}$ or $\text{C}_{2\text{-}4}\text{alkyl-S}$, the X group is incorporated into the molecule such that the $\text{C}_{2\text{-}4}\text{alkyl}$ is bound directly to the piperidine portion of the molecule;



is selected from the group consisting of phenyl, a five membered heteroaryl and a six membered heteroaryl;

b is an integer from 0 to 1;

R^4 is selected from the group consisting of aryl, C_{3-8} cycloalkyl, partially 5 unsaturated carbocyclyl, heteroaryl and heterocycloalkyl;

c is an integer from 0 to 3;

R^5 is selected from the group consisting of halogen, C_{1-6} alkyl, halogenated C_{1-6} alkyl, C_{1-6} alkoxy, nitro, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfonyl, amido, (C_{1-6} alkyl)amido, di(C_{1-6} alkyl)amido, 10 sulfonyl, aminosulfonyl, (C_{1-6} alkyl)aminosulfonyl or di(C_{1-6} alkyl)aminosulfonyl;

m is an integer from 0 to 1;

Y is selected from the group consisting of C_{1-4} alkyl, C_{2-4} alkenyl, O, S, NH, N(C_{1-4} alkyl), C_{1-6} alkyl-O, C_{1-6} alkyl-S, O- C_{1-6} alkyl and S- C_{1-6} alkyl-S;

R^6 is selected from the group consisting of aryl, partially unsaturated 15 carbocyclyl, C_{3-8} cycloalkyl, heteroaryl, heterocycloalkyl and benzoyloxyphenyl; wherein the aryl, partially unsaturated carbocyclyl, C_{3-8} cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, halogenated C_{1-6} alkyl, C_{1-6} alkoxy, nitro, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfonyl, amido, (C_{1-6} alkyl)amido, di(C_{1-6} alkyl)amido, 20 sulfonyl, aminosulfonyl, (C_{1-6} alkyl)aminosulfonyl, di(C_{1-6} alkyl)aminosulfonyl or triphenylmethyl;

provided that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X is CH_2 ,



is phenyl, b is 0, c is 0 and m is 0, then R^6 is selected from the group 25 consisting of partially unsaturated carbocyclyl, C_{3-8} cycloalkyl, heteroaryl, heterocycloalkyl, benzoyloxyphenyl and substituted aryl; (i.e. not aryl, not phenyl)

wherein the aryl, partially unsaturated carbocyclyl, C_{3-8} cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four 30 substituents independently selected from halogen, C_{1-6} alkyl, halogenated C_{1-6}

$\text{C}_1\text{-}\text{C}_6$ alkyl, $\text{C}_1\text{-}\text{C}_6$ alkoxy, nitro, amino, ($\text{C}_1\text{-}\text{C}_6$ alkyl)amino, di($\text{C}_1\text{-}\text{C}_6$ alkyl)amino, $\text{C}_1\text{-}\text{C}_6$ alkylsulfonyl, amido, ($\text{C}_1\text{-}\text{C}_6$ alkyl)amido, di($\text{C}_1\text{-}\text{C}_6$ alkyl)amido, sulfonyl, aminosulfonyl, ($\text{C}_1\text{-}\text{C}_6$ alkyl)aminosulfonyl, di($\text{C}_1\text{-}\text{C}_6$ alkyl)aminosulfonyl or triphenylmethyl;

5 provided further that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X

 is $\text{C}_1\text{-}\text{C}_3$ alkyl,  is phenyl, b is 0, c is 0 and m is 0, then R^6 is not substituted thiazolyl; wherein the substituent on the thiazolyl is selected from amino, $\text{C}_1\text{-}\text{C}_4$ alkylamino, di($\text{C}_1\text{-}\text{C}_4$ alkyl)amino or nitro;

provided further that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X

10 is CH_2 , b is 0, c is 0 and m is 0, and R^6 is phenyl, then  is not imidazolyl or pyrrolyl;

and pharmaceutically acceptable salts thereof.

Illustrative of the invention is a pharmaceutical composition comprising a
15 pharmaceutically acceptable carrier and any of the compounds described
above. An illustration of the invention is a pharmaceutical composition made
by mixing any of the compounds described above and a pharmaceutically
acceptable carrier. Illustrating the invention is a process for making a
pharmaceutical composition comprising mixing any of the compounds
20 described above and a pharmaceutically acceptable carrier.

Exemplifying the invention are methods of treating disorders and
conditions mediated by the ORL-1 receptor in a subject in need thereof
comprising administering to the subject a therapeutically effective amount of
25 any of the compounds or pharmaceutical compositions described above.

An example of the invention is a method of treating a condition selected
from the group consisting of anxiety, depression, substance abuse,
neuropathic pain, acute pain, migraine, asthma, cough and for improved
30 cognition, in a subject in need thereof comprising administering to the subject a


therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.

Another example of the invention is the use of any of the compounds
5 described herein in the preparation of a medicament for treating: (a) anxiety,
(b) depression, (c) substance abuse (d) neuropathic pain, (e) acute pain, (f)
migraine, (g) asthma and for (h) improved cognition, in a subject in need
thereof.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of disorders and conditions mediated by the ORL-1 receptor. More particularly, the compounds of the present invention are
15 of the formula (I)



wherein R¹, R², a, R³, n, X, A, b, R⁴, c, R⁵, m, Y and R⁶ are as
herein defined, and pharmaceutically acceptable salts thereof.

20 In an embodiment of the invention R¹ is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, substituted aryl and aralkyl. Preferably R¹ is selected from the group consisting of C₁₋₄alkyl, aryl, substituted aryl and

aralkyl, wherein the aryl group is substituted with a substituent selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, trifluoromethyl and C₅₋₆cycloalkyl. More preferably, R¹ is selected from the group consisting of n-propyl, phenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 4-methylphenyl, 4-methoxyphenyl, 4-5 cyclopentylphenyl, 3-bromophenyl, 3-chlorophenyl, 4-chloro-3-methylphenyl and 4-fluoro-3,5-dimethylphenyl.

In an embodiment of the invention R² is selected from the group consisting of hydrogen, C₁₋₆alkyl, substituted C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, 10 hydroxyaminoC₁₋₆alkyl, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, di(C₁₋₆alkyl)aminoC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, carboxyC₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, aryl, substituted aryl, C₃₋₈cycloalkyl, substituted C₃₋₈cycloalkyl, partially unsaturated carbocyclyl, substituted partially unsaturated carbocyclyl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted 15 heterocycloalkyl, C₁₋₆aralkyl, carbocyclylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocycloalkylC₁₋₆alkyl and phthalimidoylC₁₋₆alkyl. Preferably, R² is selected from the group consisting of hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, aminocarbonylC₁₋₄alkyl, carboxyC₁₋₄alkyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, 20 phthalimidoylC₁₋₄alkyl and substituted oxazolylC₁₋₄alkyl. More preferably, R² is selected from the group consisting of hydrogen, methyl, cyanomethyl, 2-hydroxyethyl, aminoethyl, dimethylaminoethyl, diethylaminoethyl, aminocarbonylmethyl, carboxymethyl, methoxycarbonylmethyl, phthalimidylethyl and 4-methoxycarbonyl-5-oxazolylmethyl.

25 In an embodiment of the invention a is an integer from 0 to 2, preferably a is an integer from 0 to 1. Preferably, R³ is selected from the group consisting of C₁₋₄alkyl and hydroxyC₁₋₄alkyl.

30 In a preferred embodiment of the invention n is 1.

In an embodiment of the invention, X is selected from the group consisting of C₁₋₆alkyl, substituted C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₄alkyl-O and C₂₋

$\text{C}_1\text{-alkyl-S}$. Preferably, X is selected from the group consisting of $\text{C}_{1-6}\text{alkyl}$, substituted $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-4}\text{alkyl-O}$ and $\text{C}_{2-4}\text{alkyl-S}$. More preferably, X is selected from the group consisting of $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{2-4}\text{alkyl-O}$, most preferably, C_1alkyl (CH_2), C_2alkyl (CH_2CH_2), C_3alkyl ($\text{CH}_2\text{CH}_2\text{CH}_2$), C_4alkyl ($\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2$) and
5 $\text{C}_2\text{alkyl-O}$ ($\text{CH}_2\text{CH}_2\text{-O}$).

Wherein X is $\text{C}_{2-4}\text{alkyl-O}$ or $\text{C}_{2-4}\text{alkyl-S}$ group, X is incorporated into the molecule such that the $\text{C}_{2-4}\text{alkyl}$ is bound directly to the piperidine portion of the molecule

10 In an embodiment of the invention  is selected from the group consisting of phenyl, a five membered heteroaryl and a six membered

 heteroaryl, preferably  is selected from phenyl, a five membered heteroaryl other than imidazolyl or pyrrolyl and a six membered heteroaryl.

15 More preferably,  is selected from the group consisting of phenyl, furyl, thienyl, pyridyl and pyrazolyl.

In an embodiment of the invention b is 0. In another embodiment of the invention c is an integer from 0 to 2. In yet another embodiment of the invention c is an integer from 0 to 1. In yet another embodiment of the
20 invention c is 0.

In an embodiment of the invention R^5 is selected from the group consisting of halogen, fluorinated $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{1-4}\text{alkyl}$. Preferably R^5 is selected from the group consisting of halogen, methyl and trifluoromethyl.

25 More preferably R^5 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl. More preferably still R^5 is selected from the group consisting of fluoro, methyl and trifluoromethyl, more preferably still R^5 is selected from fluoro or methyl.

In an embodiment of the invention, Y is selected from the group consisting of C₁₋₄alkyl, C₂₋₄alkenyl, O, S, NH, N(C₁₋₄alkyl), C₁₋₆alkyl-O, C₁₋₆alkyl-S, O-C₁₋₆alkyl and S-C₁₋₆alkyl-S. Preferably, Y is selected from the group consisting of O, C₁₋₄alkyl-O, C₂₋₄alkenyl and C₁₋₄alkyl. More preferably, Y is selected from the group consisting of O, CH₂-O, CH=CH and CH₂.

In an embodiment of the invention, R⁶ is selected from the group consisting of aryl, substituted aryl, partially unsaturated carbocyclyl, substituted 5 partially unsaturated carbocyclyl, C₃₋₈cycloalkyl, substituted C₃₋₈cycloalkyl, heteroaryl, substituted heteroaryl, heterocycloalkyl and substituted heterocycloalkyl. Preferably, R⁶ is selected from the group consisting of aryl, partially unsaturated carbocyclyl, heteroaryl, heterocycloalkyl, hydroxyphenyloxymethyl and benzoxyloxyphenyl, wherein the aryl, heteroaryl or heterocycloalkyl is optionally substituted with one to two substituents independently selected from halogen, acetyl, C₁₋₄alkyl, C₁₋₄alkoxy, trifluoromethyl, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, cyano, nitro, oxo, t-butoxycarbonyl and triphenylmethyl. More preferably, R⁶ is selected from the 10 group consisting of 3-methylphenyl, 4-methylphenyl, 3,5-dichlorophenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 3-pyridyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 1-naphthyl, 2-naphthyl, 2-(1-Boc-pyrrolyl), 1-(1,2,3,4-tetrahydronaphthyl), phenyl, 4-dimethylaminophenyl, 4-pyridyl, 3-quinolinyl, 2-benzothienyl, 2-benzofuryl, 5-indolyl, 2-thiazolyl, 5-chloro-2-thienyl, 5-acetyl-2-thienyl, 5-methyl-2-thienyl, 5-cyano-2-thienyl, 4-methyl-2-thienyl, 3,5-dimethyl-15 25 4-isoxazolyl, 3-pyridyl, 4-chlorophenyl, 1-(5,6,7,8-tetrahydronaphthyl), 4-hydroxyphenyloxymethyl, 1-piperidinyl, 1-(1,2,3,4-tetrahydroquinolinyl), 2-(1,2,3,4-tetrahydroisoquinolinyl), 1-pyrrolidinyl, 1-phthalimidoyl, 1-imidazolyl, 3-imidazolyl, 1-triphenylmethyl-3-imidazolyl, 1-(2-piperidinyl), 3-chlorophenyl, 4-nitrophenyl, 4-bromophenyl, 4-chlorophenyl and benzoxyloxyphenyl. Most preferably, R⁶ is selected from the group consisting of 3-methylphenyl, 4-methylphenyl, 3,5-dichlorophenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 3-pyridyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 1-naphthyl, 2-naphthyl, 2-(1-Boc-pyrrolyl), 1-(1,2,3,4-tetrahydronaphthyl), phenyl, 4-

dimethylaminophenyl, 4-pyridyl, 3-quinolinyl, 2-benzothienyl, 2-benzofuryl, 5-indolyl, 5-chloro-2-thienyl, 5-acetyl-2-thienyl, 5-methyl-2-thienyl, 5-cyano-2-thienyl, 4-methyl-2-thienyl, 3,5-dimethyl-4-isoxazolyl, 3-pyridyl, 4-chlorophenyl, 1-(5,6,7,8-tetrahydronaphthyl), 4-hydroxyphenyloxymethyl, 1-piperidinyl, 1-(1,2,3,4-tetrahydroquinolinyl), 2-(1,2,3,4-tetrahydroisoquinolinyl), 1-pyrrolidinyl, 1-phthalimidoyl, 1-imidazolyl, 3-imidazolyl, -triphenylmethyl-3-imidazolyl, 1-(2-piperidinyl), 3-chlorophenyl, 4-nitrophenyl, 4-bromophenyl 4-chlorophenyl and benzyloxyphenyl.

10 In an embodiment of the invention R⁶ is not thiazolyl or substituted

thiazolyl. In another embodiment of the invention,  is not imidazolyl or pyrrolyl.

As used herein, "halogen" shall mean chlorine, bromine, fluorine and
15 iodine.

As used herein, the term "alkyl", whether used alone or as part of a substituent group, include straight and branched chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like. Unless otherwise noted, "lower" when used with alkyl means a carbon chain composition of 1-4 carbon atoms.

As used herein, unless otherwise noted, "alkoxy" shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For
25 example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.

As used herein, unless otherwise noted, "aryl" shall refer to unsubstituted carbocyclic aromatic groups such as phenyl, naphthyl, and the like.

As used herein, unless otherwise noted, "aralkyl" shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like. For example, benzyl (phenylmethyl), phenylethyl, phenylpropyl, naphthylmethyl, and the like.

5

As used herein, unless otherwise noted, the term "cycloalkyl" shall mean any stable 3-8 membered monocyclic, carbon based, saturated ring system, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

10

As used herein, unless otherwise noted, the term "carbocyclyl" shall mean any four to fourteen membered monocyclic or bicyclic, carbon based ring structure. Similarly, unless otherwise noted, the term "partially unsaturated carbocyclyl" shall mean any four to fourteen membered monocyclic or bicyclic, 15 carbon based ring structure containing at least one unsaturated bond. Suitable examples include 1,2,3,4-tetrahydronaphthyl, cyclohexen-1-yl, and the like.

As used herein, unless otherwise noted, "heteroaryl" shall denote any five or six membered monocyclic aromatic ring structure containing at least one 20 heteroatom selected from the group consisting of O, N and S, optionally containing one to three additional heteroatoms independently selected from the group consisting of O, N and S; or a nine or ten membered bicyclic aromatic ring structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to four additional heteroatoms 25 independently selected from the group consisting of O, N and S. The heteroaryl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.

Examples of suitable heteroaryl groups include, but are not limited to, 30 pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furazanyl, indolizinyl, indolyl, isoindolinyl, indazolyl, benzofuryl, benzothienyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, isothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,

naphthyridinyl, pteridinyl, and the like. Preferred heteroaryl groups include thienyl, pyridyl, furyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, indolyl, isoindolyl, quinolinyl, benzofuryl and benzothienyl.

5 As used herein, the term "heterocycloalkyl" shall denote any five to seven membered monocyclic, saturated or partially unsaturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to three additional heteroatoms independently selected from the group consisting of O, N and S; or a nine to ten membered
10 saturated, partially unsaturated or partially aromatic bicyclic ring system containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to four additional heteroatoms independently selected from the group consisting of O, N and S. The heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the
15 result is a stable structure.

Examples of suitable heterocycloalkyl groups include, but are not limited to, pyrrolinyl, pyrrolidinyl, dioxalanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, indolinyl, chromenyl, 3,4-methylenedioxyphenyl, 2,3-dihydrobenzofuryl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, and the like. Preferred heterocycloalkyl groups include pyrrolidinyl, piperidinyl, imidazolyl, 1,2,3,4-tetrahydroisoquinolinyl and 1,2,3,4-tetrahydroquinolinyl.

As used herein, the notation "*" shall denote the presence of a
25 stereogenic center.


When a particular group is "substituted" (e.g., alkyl, aryl, carbocyclyl, heterocycloalkyl, heteroaryl), that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three
30 substituents, most preferably from one to two substituents, independently selected from the list of substituents.

Suitable alkyl substituents include hydroxy, carboxy, cyano, amino, C₁-alkylamino, di(C₁-₆alkyl)amino, hydroxyC₁-₆alkylamino, aminoC₁-₆alkylamino, C₁-₆alkylaminoC₁-₆alkylamino and di(C₁-₆alkyl)aminoC₁-₆alkylamino.

Suitable cycloalkyl, aryl, carbocyclyl, heteroaryl and heterocycloalkyl
 5 substituents include halogen, hydroxy, C₁-₆alkyl, halogenated C₁-₆alkyl, C₁-
 alkoxy, nitro, amino, (C₁-₆alkyl)amino, di(C₁-₆alkyl)amino, C₁-₆alkylsulfonyl,
 amido, (C₁-₆alkyl)amido, di(C₁-₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁-
 10 alkoxy)aminosulfonyl, di(C₁-₆alkyl)aminosulfonyl and C₃-₈cycloalkyl. Preferably,
 the cycloalkyl, aryl, carbocyclyl, heteroaryl and heterocycloalkyl substituents
 15 include halogen, C₁-₆alkyl, halogenated C₁-₆alkyl, C₁-₆alkoxy, nitro, amino, (C₁-
 alkoxy)amino, di(C₁-₆alkyl)amino, C₁-₆alkylsulfonyl, amido, (C₁-₆alkyl)amido,
 di(C₁-₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁-₆alkyl)aminosulfonyl and di(C₁-
 alkoxy)aminosulfonyl.

15 With reference to substituents, the term "independently" means that
 when more than one of such substituents is possible, such substituents may be
 the same or different from each other.

Under standard nomenclature used throughout this disclosure, the
 20 terminal portion of the designated side chain is described first, followed by the
 adjacent functionality toward the point of attachment. Thus, for example, a
 "phenylC₁-C₆alkylcarbonylaminoC₁-C₆alkyl" substituent refers to a group
 of the formula



25 Abbreviations used in the specification, particularly the Schemes and
 Examples, are as follows:

AcOH	=	Acetic Acid
aq.	=	Aqueous

DCE	=	Dichloroethane
DCM	=	Dichloromethane
DEAD	=	Diethylazodicarboxylate
DIAD	=	Diisopropylazodicarboxylate
DIPEA or DIEA	=	Diisopropylethylamine
DMF	=	N,N-Dimethylformamide
DME	=	1,2-dimethoxyethane
DMSO	=	Dimethylsulfoxide
EGTA	=	Ethylene glycol-bis[β-aminoethylester]-N,N,N',N'-tetraacetic acid
Et ₂ O	=	Diethyl ether
EtOAc	=	Ethyl acetate
EtOH	=	Ethanol
HPLC	=	High Pressure Liquid Chromatography
KO-t-Bu	=	Potassium t-butoxide
MeOH	=	Methanol
Ms	=	mesyl group (-SO ₂ -CH ₃)
Na(OAc) ₃ BH	=	Sodium triacetoxyborohydride
NaO-t-Bu	=	Sodium t-butoxide
NMP	=	N-methyl-2-pyrrolidinone
PEI	=	Polyethylenimine
Ph	=	Phenyl
Pd ₂ (OAc) ₂	=	Palladium(II)acetate
Pd ₂ (dba) ₃	=	Tris(dibenzylidene acetone)dipalladium(0)
Pd(PPh ₃) ₄	=	tetrakis(triphenylphosphine)palladium(0)
PdCl ₂ (PPh ₃) ₂	=	di(chloro)di(triphenylphosphine)palladium(0)
t-BOC or Boc	=	Tert-Butoxycarbonyl
t-Bu	=	Tert-butyl
TEA or Et ₃ N	=	Triethylamine
TFA	=	Trifluoroacetic Acid
THF	=	Tetrahydrofuran
TLC	=	Thin Layer Chromatography
TMOF	=	Trimethylorthoformate

Tris HCl or Tris-Cl = Tris[hydroxymethyl]aminomethyl hydrochloride

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

5

The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes 10 alleviation of the symptoms of the disease or disorder being treated.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the 15 specified ingredients in the specified amounts.

For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of compounds according to this invention or of their 20 pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, 25 tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium 30 salts. Thus, representative pharmaceutically acceptable salts include the following:


acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate,


5 hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate,

10 stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.

Compounds of formula (I) wherein n is an integer from 0 to 1, m is an integer from 0 to 1, Y is selected from C₂-4 alkenyl and R⁶ is aryl or heteroaryl,

15 may be prepared according to the process outlined in Scheme 1.





Scheme 1


More particularly, a compound of formula (II), a known compound or

5 compound prepared by known methods, is reacted with a suitably substituted
compound of formula (III), a known compound or compound prepared by
known methods, in the presence of a base such as DIPEA, TEA, pyridine,
 Na_2CO_3 , K_2CO_3 , and the like, wherein the base is present in an amount of at
least one equivalent, in an organic solvent such as acetonitrile, DMF, DMSO,
10 NMP, and the like, preferably at an elevated temperature, to yield the
corresponding compound of formula (IV).

When the base is an inorganic base such as Na_2CO_3 , K_2CO_3 , and the like, the compound of formula (II) is reacted with the compound of formula (III) in an aprotic solvent such as DMF, DMSO, NMP, and the like.

15 The compound of formula (IV) is reacted with a suitably substituted
boronic acid, a compound of formula (V), a known compound or compound
prepared by known methods, in the presence of a catalyst such as $\text{Pd}(\text{PPh}_3)_4$,
 $\text{PdCl}_2(\text{PPh}_3)_2$, and the like, in the presence of a base such as Na_2CO_3 ,
 NaHCO_3 , K_3PO_4 , and the like, in a non-protic organic solvent or mixture thereof
20 such as toluene, toluene/ethanol, DME, DMF, and the like, to yield the
corresponding compound of formula (Ia).

Compounds of formula (I) wherein n is an integer from 0 to 1, m is 0 and R⁶ is aryl or heteroaryl, may alternatively be prepared according to the process outlined in Scheme 2.




5

Scheme 2

Specifically, a suitably substituted bromoaldehyde, a compound of formula (VI), a known compound or compound prepared by known methods, is reacted with a suitably substituted boronic acid, a compound of formula (VII), a known compound or compound prepared by known methods, in the presence of a catalyst such as Pd(PPh₃)₄, PdCl₂(PPh₃)₂, and the like, in the presence of a base such as Na₂CO₃, NaHCO₃, K₃PO₄, and the like, in a non-protic organic solvent or mixture thereof such as toluene, toluene/ethanol, DME, DMF, benzene, and the like, to yield the corresponding compound of formula (VIII).

The compound of formula (VIII) is reacted with a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, in the presence of a reducing agent such as sodium triacetoxyborohydride ($\text{Na(OAc)}_3\text{BH}$), sodium cyanoborohydride (NaCNBH_3), and the like, optionally in the presence of an acid such as acetic acid (AcOH), and the like, in an organic solvent such as DCE, THF, acetonitrile, and the like, to yield the corresponding compound of formula (Ib).


The compound of formula (VIII) may alternatively be prepared according to the process outlined in Scheme 3.



Scheme 3

Accordingly, a suitably substituted compound of formula (IX), a known compound or compound prepared by known methods, is reacted with a suitably substituted compound of formula (X), a known compound or compound prepared by known methods, in the presence of a catalyst such as Pd(PPh₃)₄, PdCl₂(PPh₃)₂, and the like, in the presence of a base such as aqueous NaHCO₃, Na₂CO₃, K₃PO₄, and the like, in an organic solvent such as DME, DMF, toluene, benzene, and the like, to yield the corresponding compound of formula (VIII).

Compounds of formula (I) wherein n is 1, X is CH₂, m is 1, Y is O and R⁶ is aryl or heteroaryl, may be prepared according to the process in Scheme 4.



Scheme 4

5 More particularly, for compounds of formula (I) wherein Y is O and R⁶ is bound to the O through a tetrahedral carbon (i.e. a carbon atom that is not part of a unsaturated bond), a compound of formula (XI), a known compound or compound prepared by known methods, is reacted with a suitably substituted alcohol, a compound of formula (XII), a known compound or compound

10 prepared by known methods, in the presence of an activating agent such as tributylphosphine, triphenylphosphine, diphenyl-2-pyridylphosphine, and the like, in an anhydrous organic solvent such as benzene, THF, DCM, and the like, (via a Mitsunobu reaction) in the presence of a dehydrating agent such as 1,1'-(azodicarbonyl)dipiperidine, diethylazodicarboxylate,

15 diisopropylazodicarboxylate, and the like; to yield the corresponding compound of formula (XIII).

For compounds of formula (I) wherein Y is O and R⁶ is bound to the O through a carbon atom that is part of a double bond (i.e. a carbon atom which is part of an aryl, heteroaryl or other unsaturated group), the compound of formula (XI) is reacted with a suitably substituted boronic acid, a compound of formula (VII), a known compound or compound prepared by known methods, in the presence of a catalyst such as copper (II) acetate, and the like, in the presence of an base such as TEA, pyridine, and the like, in the presence of molecular sieves, preferably 4 Angstrom molecular sieves, in an organic solvent such as DCM, DCE, and the like, at ambient temperature, to yield the corresponding compound of formula (XIII).

Alternatively, the compound of formula (XIII) may be prepared by reacting a compound of formula (XI) wherein the hydroxy (OH) group is replaced with a fluoro, bromo or triflate with a compound of formula (XII), as defined above, in the presence of a base such as K₂CO₃, sodium carbonate, sodium bicarbonate, and the like, in a dipolar aprotic solvent such as (CH₃)₂NCOCH₃, DMF, DMSO, and the like.

The compound of formula (XIII) is reacted with a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, in the presence of a reducing agent such as sodium triacetoxyborohydride, sodium cyanoborohydride, and the like, in an organic solvent such as DCE, THF, acetonitrile, and the like, to yield the corresponding compound of formula (Ic).


One skilled in the art will recognize that compounds of formula (I) wherein m is 1 and Y is S may similarly be prepared according to the process outlined above with appropriate selection and substitution of suitably substituted starting materials.

One skilled in the art will recognize that compounds of formula (I) wherein m is 1 and Y is NH or N(C₁₋₄alkyl) may similarly be prepared according to the process outlined in Scheme 1 with suitable selection and substitution of


suitably substituted starting materials (i.e. amination of the arylbromide compound of formula (IV) by reacting with a suitably substituted amine of the formula R^6-NH_2 , in the presence of palladium (0) catalysts (e.g. Buckwald reaction) as described in *Accts. Chem. Res.* 1998, 31, 805.).

5

Compounds of formula (I) wherein n is an integer from 0 to 1, m is an integer from 0 to 1, Y is selected from C_{2-4} -alkenyl and R^6 is aryl or heteroaryl, may alternatively be prepared according to the process outlined in Scheme 5.



10



Scheme 5

Accordingly, a suitably substituted compound of formula (XIV), a known


- 5 compound or compound prepared by known methods, is reacted with a suitably substituted boronic acid, a compound of formula (V), a known compound or compound prepared by known methods, in the presence of a catalyst such as Pd(PPh₃)₄, PdCl₂(PPh₃)₂, and the like, in the presence of a base such as aqueous NaHCO₃, Na₂CO₃, K₃PO₄, and the like, in an organic
- 10 solvent such as DME, benzene, and the like, to yield the corresponding compound of formula (XV).

The compound of formula (XV) is reacted with methanesulfonyl chloride, in the presence of an organic base such as TEA, DIPEA, N-methylmorpholine, and the like, in an aprotic organic solvent such as DCM, THF, acetonitrile, CHCl₃, and the like, to yield the corresponding compound of formula (XVI).

The compound of formula (XVI) is reacted with a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, in the presence of a base such as TEA, DIPEA, pyridine, and the like, in an aprotic organic solvent such as DCE, THF, acetonitrile, NMP, and the like, to yield the corresponding compound of formula (Id).

A

Compounds of formula (I) wherein n is 1, X is CH₂, is phenyl, m is 1, Y is -CH₂- and the -(Y)_m-R⁶ group is bound at the 3 or 4 position (not the 2 position), may be prepared according to the process outlined in Scheme 6.



5

Scheme 6.


More specifically, a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, is reacted with 1,4- or 1,3-bis-(chloromethyl)benzene, a known compound, in the presence of an organic base such as DIPEA, TEA, N-methylmorpholine, and the like, in an organic solvent such as NMP, DMF, acetonitrile, and the like, to yield the corresponding compound of formula (XVII), wherein the chloromethyl is bound at the 4- or 3- position, respectively.

15 The compound of formula (XVII) is reacted with a suitably substituted compound of formula (XVIII), a known compound or compound prepared by

known methods, in the presence of a base such as TEA, DIPEA, K_2CO_3 , Na_2CO_3 , and the like, in an organic solvent such as NMP, DMF, THF, and the like, to yield the corresponding compound of formula (Ie), wherein the $-(Y)_m-R^6$ group is bound at the 4 or 3 position, respectively,

5

Alternatively, the compound of formula (II) may be reacted with 1,3- or 2,6-di(chloromethyl)pyridyl, to yield the corresponding compound wherein the




portion of the molecule is a suitably substituted pyridylmethyl rather than a suitably substituted benzyl.


10

Alternatively, compounds of formula (I) ($X)_n$ is CH_2 , is phenyl, m is 1, Y is $-CH_2-$ and the $-(Y)_m-R^6$ group is bound at the 3 or 4 position (not the 2 position), may be prepared according to the process outlined in Scheme 7.

15 Step 1:



Step 2:




Scheme 7

5 Accordingly, 1,2-, 1,3 or 1,4- substituted bischloromethyl benzene, a known compound is reacted with a suitably substituted compound of formula (XVIII), a known compound or compound prepared by known methods, in an organic solvent such as THF, DMSO, DMF, and the like, in the presence of a base such as NaH, Na₂CO₃, K₂CO₃, N-butyl lithium, and the like, to yield a
 10 mixture of the mono- and di-substituted benzene compounds of formula (XIX) and (XX).

The mono-substituted compound of formula (XIX) is preferably isolated and then reacted with a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, in the presence of an
 15 organic base such as DIPEA, TEA, pyridine, N-methylmorpholine, and the like, in an organic solvent such as NMP, THF, DMF, and the like, to yield the corresponding compound of formula (If).

Compounds of formula (I) wherein n is 0 may alternatively be prepared
 20 by adapting the process described in *J. Org. Chem.* 1997, 62, 1264, and references cited therein. More particularly, the compounds of formula (I) wherein n is 0 may be prepared according to the process outlined in Scheme 8.



Scheme 8

Accordingly, a suitably substituted compound of formula (XXI), wherein
 5 each Q is independently selected from $-Br$, $-Cl$ or $-OSO_2CF_3$, a known
 compound or compound prepared by known methods is reacted with a suitably
 substituted boronic acid, a compound of formula (V), a known compound or
 compound prepared by known methods, in the presence of a catalyst such as
 $Pd(PPh_3)_4$, $PdCl_2(PPh_3)_2$, and the like, in an organic solvent such as DME,
 10 DMF, toluene, and the like, to yield the corresponding compound of formula
 (XXII).


The compound of formula (XXII) is reacted with a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, in the presence of a catalyst such as Pd₂(dba)₃, Pd₂(OAc)₂, and the like, in the presence of a base such as KO-t-Bu, NaO-t-Bu, K₃PO₄, and the like, in an organic solvent such as THF, DME, toluene, and the like, to yield the corresponding compound of formula (Ig).

Alternatively, a suitably substituted compound of formula (XXI), wherein each Q is independently selected from, -Br, -Cl or -OSO₂CF₃, a known compound or compound prepared by known methods, is reacted with a suitably substituted compound of formula (II), a known compound or compound prepared by known methods, in the presence of a catalyst such as Pd₂(dba)₃, Pd₂(OAc)₂, and the like, in the presence of a base such as KO-t-Bu, NaO-t-Bu, K₃PO₄, and the like, in an organic solvent such as THF, DME, toluene, and the like, to yield the corresponding compound of formula (XXIII)

The compound of formula (XXIII) is reacted with a suitably substituted boronic acid, a compound of formula (V), a known compound or compound prepared by known methods, in the presence of a catalyst such as Pd(PPh₃)₄, PdCl₂(PPh₃)₂, and the like, in the presence of a base such as Na₂CO₃, NaHCO₃, and the like, in an organic solvent such as DME, DMF, toluene, and the like, to yield the corresponding compound of formula (Ig).

Compounds of formula (I) wherein R¹ and R² are varied, may be prepared from suitably substituted starting materials according to the processes disclosed in U.S. Patent No. 3,155,699 (Issued Nov. 3, 1964) and/or in PCT Application WO 99/59997.

Compounds of formula (I) wherein R² is selected from carboxy substituted C₁₋₆alkyl, aminoC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl or C₁₋₆alkylcarbonylC₁₋₆alkyl, wherein the amino portion of the R² group may be optionally substituted with one or two C₁₋₆alkyl groups, may be prepared according to the process outlined in Scheme 9.



Scheme 9

Accordingly, a suitably substituted compound of formula (Ih), (a
 5 compound of formula (I) wherein R² is hydrogen), a known compound or
 compound prepared by known methods, is reacted with a suitably substituted
 compound of formula (XXIV), a known compound or compound prepared by
 known methods, in the presence of a strong base such as NaH, KH, sodium
 trimethylsilylamide, and the like, in an organic solvent such as DMF, NMP,
 10 THF, and the like, to yield the corresponding compound of formula (I).

Alternatively, the compound of formula (Ih) is reacted with a compound
 of formula (XXIV), wherein the hydroxy, carboxy or amino portion of the R²
 group is protected, followed by de-protection by known methods, to yield the
 corresponding compound of formula (I).

15

Where the compounds according to this invention have at least one
 chiral center, they may accordingly exist as enantiomers. Where the
 compounds possess two or more chiral centers, they may additionally exist as
 diastereomers. It is to be understood that all such isomers and mixtures
 20 thereof are encompassed within the scope of the present invention.
 Furthermore, some of the crystalline forms for the compounds may exist as
 polymorphs and as such are intended to be included in the present invention.

In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

5 Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The
10 compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by
15 formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

20 During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic
25 Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

30 The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible *in vivo* into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a

compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier,

5 1985.

Following the procedures described herein, selected compounds of the present invention were prepared as listed in Table 1-7.

10

TABLE 1

Cmpd #	m	Y	R ⁶	MS MH ⁺
1	0	-	phenyl	398.2
2	0	-	3-thienyl	404.1
3	0	-	4-methylphenyl	412.2
4	0	-	3,5-dichlorophenyl	467.2
5	0	-	4-methoxyphenyl	428.2
6	0	-	3-pyridyl	399.2
7	0	-	3-trifluoromethylphenyl	466.2
8	0	-	2-furyl	388.2
9	0	-	2-thienyl	404.1
10	0	-	3-furyl	388.2
11	0	-	2-pyrrolyl	387.2
12	0	-	1-naphthyl	448.2
13	0	-	2-(1-Boc-pyrrolyl)	487.3

14	1	-O-	1-(1,2,3,4-tetrahydronaphthyl)	468.3
15	0	-	2-naphthyl	448.2
16	1	-CH ₂ -O-	phenyl	428.4
17	0	-	4-dimethylaminophenyl	441.3
18	0	-	4-pyridyl	399.1
19	0	-	3-quinolinyl	449.2
20	0	-	2-benzothienyl	454.1
21	0	-	2-benzofuryl	438.1
22	0	-	5-indolyl	437.1
23	1	trans -CH=CH-	phenyl	424.2
24	0	-	2-thiazolyl	405.1
25	0	-	5-chloro-2-thienyl	438.0
26	0	-	5-acetyl-2-thienyl	446.1
27	0	-	5-methyl-2-thienyl	418.1
28	0	-	5-cyano-2-thienyl	429.0
29	0	-	4-methyl-2-thienyl	418.1
30	0	-	3,5-dimethyl-4-isoxazolyl	417.1
57	1	O	phenyl	414.1
58	0	-	3-imidazolyl	388.1
59	0	-	1-triphenylmethyl-3-imidazolyl	630.3

TABLE 2

Cmpd #	R ¹	R ²	(R ³) _a	MW MH ⁺
31	phenyl	dimethylaminoethyl	a=0	475.0
32	4-fluorophenyl	hydrogen	a=0	422.0
33	phenyl	diethylaminoethyl	a=0	503.2
34	phenyl	aminoethyl	a=0	404.0
35	phenyl	methyl	a=0	418.2
36	phenyl	aminocarbonyl methyl	a=0	431.1
38	4-fluorophenyl	hydrogen	5-methyl	436.1
39	phenyl	2-hydroxyethyl	a=0	448.1
40	phenyl	methoxycarbonyl methyl	a=0	476.1
41	phenyl	carboxymethyl	a=0	462.1
42	3-trifluoro methylphenyl	hydrogen	a=0	472.0
43	4-methylphenyl	hydrogen	a=0	418.1
44	phenyl	phthalimidoylethyl	a=0	577.0
45	n-propyl	hydrogen	a=0	370.1
46	4-cyclopentyl phenyl	hydrogen	a=0	472.1
47	4-methoxyphenyl	hydrogen	a=0	434.1

60	4-chloro-3-methylphenyl	hydrogen	a=0	453.1
61	4-fluoro-3,5-dimethylphenyl	hydrogen	a=0	450.1
62	3-bromophenyl	hydrogen	a=0	483.1
63	3-chlorophenyl	hydrogen	a=0	438.1
64	phenylmethyl	hydrogen	a=0	418.1
65	phenyl	4-methoxycarbonyl-5-oxazolymethyl	a=0	543.6

TABLE 3

Cmpd #	R ¹	R ²	(R ³) _a	MW MH ⁺				
				Cmpd #	R ¹	R ²	(R ³) _a	MW MH ⁺
48	phenyl	methyl	a=0					402.1
49	phenyl	cyanomethyl	a=0					413.1
50	4-fluorophenyl	hydrogen	a=0					406.1
51	4-fluorophenyl	hydrogen	5-methyl					420.1
52	3-trifluoro methylphenyl	hydrogen	a=0					456.2
53	4-methylphenyl	hydrogen	a=0					402.2
54	n-propyl	hydrogen	a=0					354.1
55	4-methoxyphenyl	hydrogen	a=0					418.2

56	4-cyclopentyl phenyl	hydrogen	a=0	456.2
66	4-chloro-3-methylphenyl	hydrogen	a=0	436.1
67	4-fluoro-3,5-dimethylphenyl	hydrogen	a=0	434.1
68	3-bromophenyl	hydrogen	a=0	467.1
69	3-chorophenyl	hydrogen	a=0	422.1
70	phenylmethyl	hydrogen	a=0	402.1

TABLE 4

Cmpd #	m	Y	R ^b	MS MH ⁺
101	1	-CH ₂ -O-	phenyl	428.3
102	1	-O-	1-(1,2,3,4-tetrahydronaphthyl)	468.3
103	0	-	3-thienyl	404.3
104	0	-	1-naphthyl	448.4
105	0	-	4-methylphenyl	412.2
106	0	-	phenyl	398.2
107	0	-	3-trifluoromethylphenyl	466.4
108	0	-	3,5-dichlorophenyl	466.3
109	0	-	3-pyridyl	399.4
110	0	-	4-methoxyphenyl	428.4
111	1	-CH ₂ -O-	4-chlorophenyl	462.4

112	1	-CH ₂ -O-	1-naphthyl	478.4
113	1	-CH ₂ -O-	1-(5,6,7,8-tetrahydronaphthyl)	482.3
114	1	-CH ₂ -O-	4-methoxyphenyl	458.3
115	1	-CH ₂ -O-	4-benzoyloxyphenyl	548.3
116	1	-CH ₂ -O-	4-hydroxyphenyl	444.2
117	1	-CH ₂ -	1-piperidinyl	419.3
118	1	-CH ₂ -	1-(1,2,3,4-tetrahydroquinolinyl)	467.3
119	1	-CH ₂ -	2-(1,2,3,4-tetrahydroisoquinolinyl)	467.3
120	1	-CH ₂ -	1-pyrrolidinyl	405.3
121	1	-CH ₂ -	1-phthalimidoyl	481.3
122	1	-CH ₂ -	1-imidazolyl	402.3
123	1	-CH ₂ -	1-(2-piperidinoyl)	433.4
124	1	-CH ₂ -O-	3-chlorophenyl	462.2
125	1	-CH ₂ -O-	4-nitrophenyl	473.2

TABLE 5

Cmpd #	m	Y	R ⁶	MS MH ⁺
201	1	-CH ₂ -O-	phenyl	428.31
202	1	-O-	1-(1,2,3,4-tetrahydronaphthyl)	468.2
203	0	-	phenyl	398.3

CN1CCCC2(C(=O)N(c3ccccc3)C1)CCc3ccccc3R6

204	0	-	3-trifluoromethylphenyl	466.3
205	0	-	3-thienyl	404.3
206	0	-	3-pyridyl	399.3
207	0	-	3,5-dichlorophenyl	466.2
208	0	-	1-naphthyl	448.4
209	0	-	4-methoxyphenyl	428.3
210	0	-	4-methylphenyl	412.2
211	1	-CH ₂ -	1-piperidinyl	419.3
213	1	-CH ₂ -	1-(2-piperidonyl)	433.4
214	1	-CH ₂ -	1-pyrrolidinyl	405.3
215	1	-CH ₂ -	1-imidazolyl	402.3
216	1	-CH ₂ -	1-phthalimidoyl	481.2
217	1	-CH ₂ -	2-(1,2,3,4-tetrahydroisoquinolinyl)	467.3
218	1	-CH ₂ -	1-(1,2,3,4-tetrahydroquinolinyl)	467.3

TABLE 6

Cmpd #	(R ⁵) _c	R ⁶	MS MH ⁺
301	2-furyl	5-(4-bromophenyl)	467.1
302	2-furyl	5-(4-chlorophenyl)	422.2

303	2-chloro-4-methyl-3-pyrazoyl	phenyl	436.0
304	2-methyl-3-pyrazoyl	4-(2-thienyl)	408.0
305	2-thienyl	3(2-thienyl)	410.0
306	3-pyridyl	2-(m-tolyl)	413.1

TABLE 7

Cmpd #	(X) _n	R ⁶	MS MH ⁺
401	(CH ₂) ₂	2-thienyl	418.1
402	(CH ₂) ₂	3-thienyl	418.0
403	(CH ₂) ₃	2-thienyl	432.0
404	(CH ₂) ₃	3-thienyl	432.1
405	(CH ₂) ₄	2-thienyl	446.1

Table 8

Cmpd #	R ²	(X) _n	R ⁶	MS MH ⁺
406	H	-CH ₂ CH ₂ -O-	2-phenyl	428.0
407	dimethylamino-ethyl	-CH ₂ CH ₂ -	2-(2-thienyl)	489.2
408	diethylamino-ethyl	-CH ₂ CH ₂ -	2-(2-thienyl)	517.1
409	Methoxycarbonyl-methyl	-CH ₂ CH ₂ -	2-(2-thienyl)	490.1
410	carboxymethyl	-CH ₂ CH ₂ -	2-(2-thienyl)	476.1
411	H	-CH ₂ CH ₂ -	3-(2-thienyl)	418.0
412	H	-CH ₂ CH ₂ -	4-(2-thienyl)	418.0

Table 9

Cmpd #	R ⁵	R ⁶	MS MH ⁺
501	5-fluoro	2-(2-thienyl)	422.0

502	5-trifluoromethyl	2-(2-thienyl)	472.0
503	6-fluoro	2-(3-thienyl)	422.0
504	4-fluoro	2-(2-thienyl)	422.0
505	4-fluoro	2-(3-thienyl)	422.0

Table 10

Cmpd #	X	R ⁶	MS MH ⁺
506	fluoro	2-thienyl	464.1

The present invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate,

dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as

5 homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 5 to about 1000 mg of the active

10 ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be

15 separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

20

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil,

25 coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

30

The method of treating disorders mediated by the ORL-1 receptor described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein

and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 1 mg and 1000 mg, preferably about 10 to 500 mg, of the compound, and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixers, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The liquid forms may include suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyl-eneoxidepolylysine substituted with palmitoyl residue. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

25

Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of disorders mediated by the ORL-1 receptor is required.

30 The daily dosage of the products may be varied over a wide range from 5 to 1,000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 1.0, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 milligrams of the active ingredient for the


symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 20 mg/kg of body weight per day. Preferably, the range is from about 0.2 mg/kg to about 10 mg/kg of body weight per day, and especially from 5 about 0.5 mg/kg to about 10 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of 10 administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.

15 The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

EXAMPLE 1

20 1-Phenyl-8-[2-[3-(trifluoromethyl)phenyl]benzyl]-1,3,8-triaza-spiro[4.5]decan-4-one (Compound #7).



Step A:

A mixture of 2-bromobenzyl bromide (0.70 mL, 4.54 mmol), 1-phenyl-25 1,3,8-triazaspiro[4.5]decan-4-one (1.036 g, 0.0045 mol) and

diisopropylethylamine (0.86 mL, 4.95 mmol) in acetonitrile was refluxed for 1 hr. The mixture was cooled to room temperature, the precipitated product collected by filtration and dried in a vacuum oven at room temperature overnight to yield the product as a white solid.

5 MS (loop pos.) MH^+ = 401.26 (25%), 403.26 (23%);
 1H NMR (300 MHz, DMSO-d₆) δ 1.50-1.60 (m, 2H), 2.50-2.60 (m, 2H), 2.70-2.90 (m, 4H), 3.70 (s, 2H), 4.60 (s, 2H), 6.70-6.75 (m, 1H), 6.80-6.85 (m, 2H), 7.15-7.25 (m, 3H), 7.35-7.40 (m, 1H), 7.55-7.70 (m, 2H), 8.65 (s, 1H).


10 Step B:

To a mixture of the product of Step A (105 mg, 0.260 mmol) and 2 M aqueous Na₂CO₃ (1.5 mL) in toluene (7 mL) was added a solution of 3-trifluoromethylphenyl boronic acid (108 mg, 0.572 mmol) in ethanol (2.50 mL). The resulting mixture was stirred at room temperature under nitrogen atmosphere, treated with Pd(PPh₃)₄ (18 mg, 6 mol %) and refluxed for 7 hrs. The solution was cooled to room temperature, the dark brown reaction mixture was diluted with ethyl acetate (75mL) and washed with water (2 X 75 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated to yield the crude product. The crude product was purified by chromatography on the Biotage apparatus (2% methanol in CHCl₃) to yield the title product as a white solid.

15 MS (loop pos.) MH^+ = 466.2 (100%)
 1H NMR (300 MHz, CDCl₃) δ 1.50-1.60 (m, 2H), 2.50-2.60 (m, 2H), 2.70-2.90 (m, 4H), 3.40 (s, 2H), 4.75 (s, 2H), 6.20 (s, 1H), 6.80-6.90 (m, 3H), 7.25-25 7.75 (m, 9H), 8.20 (s, 1H).

EXAMPLE 2

1-Phenyl-8-[2-(3-thienyl)benzyl]-1,3,8-triaza-spiro[4.5]decan-4-one
(Compound #2).



5 Step A:

To a mixture of 2-bromobenzaldehyde (0.32 mL, 2.70 mmol) and 3 mL of 2 M aqueous sodium carbonate in 15 mL of toluene was added thiophene-3-boronic acid (384 mg, 3.00 mmol) in ethanol (3 mL). The mixture was stirred and then treated with tetrakis(triphenylphosphine)palladium (0) (93.0 mg, 3

10 mole %) and heated to reflux under nitrogen atmosphere for 4.5 hr. The resulting solution was cooled to room temperature, the dark brown reaction mixture was diluted with ethyl acetate (75 mL) and washed with water (2 X 75 mL). The organic phase was dried over Na_2SO_4 , filtered and concentrated in vacuo to yield 2-(3-thienyl)benzaldehyde as a brown oil.

15 The reaction was repeated on a 50 mmol scale with 2-bromobenzaldehyde (5.8 mL), thiophene-3-boronic acid (7.03 g, 0.0555 mol) in ethanol (55 mL), $\text{Pd}(\text{PPh}_3)_4$ (1.7 g, 3 mol %), 2 M aqueous Na_2CO_3 (55 mL) in toluene (275 mL) to yield crude 2-(3-thienyl)benzaldehyde as an oil.

Both batches of the crude 2-(3-thienyl)benzaldehyde were combined
20 and carried onto the next step without purification.

MS (loop pos.) $\text{MH}^+ = 189$

^1H NMR (300 MHz, DMSO-d_6) δ 7.30-7.80 (m, 7H), 10.0 (s, 1H)

Step B:

To a mixture of 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (416 mg, 1.80 mmol) and crude 2-(3-thienyl)benzaldehyde (340 mg) and acetic acid (0.1 mL, 1.80 mmol) in CH₂Cl₂ (14 mL) was added sodium triacetoxyborohydride 5 (0.763 g, 3.60 mmol). The resulting mixture was stirred at room temperature for 20 hrs. The reaction mixture was quenched with 1 N aqueous NaOH and extracted with CH₂Cl₂ (2X). The combined extracts were washed with 1N aqueous NaOH, dried over K₂CO₃, filtered, and concentrated in vacuo to yield the crude product as an oil.

10 The reaction was repeated on a 6.6 mmol scale with spiropiperidine (1.53 g), crude 2-(3-thienyl)benzaldehyde (1.24 g), AcOH (0.38 mL) and Na(OAc)₃BH (2.80 g, 0.0132 mol) in CH₂Cl₂ (50 mL) reacted to yield crude product as an oil.

The total combined, crude product from both experiments described 15 above was purified by flash chromatography on silica gel (2% MeOH in CH₂Cl₂) to yield the title compound as a free base. The free base (2.15 g) was dissolved in isopropyl alcohol and acidified with 1N HCl in diethyl ether to yield the title product as a monohydrochloride salt.


MS (loop pos.) MH⁺ = 404.1 (100%)

20 ¹H NMR (300 MHz, DMSO d₆) δ 1.50-1.60 (m, 2H), 2.75-2.90 (m, 2H), 3.20-3.45 (m, 4H), 4.40 (s, 2H), 4.55 (s, 2H), 6.75-6.80 (m, 1H), 6.95-7.00 (m, 2H), 7.15-7.25 (m, 3H), 7.40-7.45(m, 1H), 7.50-7.55 (m, 2H), 7.65 (m, 1H), 7.70-7.75 (m, 1H), 7.90-7.95 (m, 1H), 8.9 (s, 1H), 10.40 (br s, 1H exchangeable)

25 Elemental Analysis For C₂₄H₂₅N₃OS·HCl·0.1H₂O:
Calculated: C, 65.25; H, 5.98; N, 9.51; Cl, 8.02; H₂O, 0.41
Measured: C, 64.93; H, 5.89; N, 9.44; Cl, 8.06; H₂O, 0.40.

Example 3

1-phenyl-8-[[4-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one (Compound #202)



5 Step A:

To a cold (0°C) heterogenous mixture of 1,2,3,4-tetrahydro-1-naphthol (2.96 g, 0.020 mol) in anhydrous benzene (100 mL) was added p-hydroxybenzaldehyde (3.66 g, 0.030 mol) and tributylphosphine (6.14 g, 0.030 mol). The resultant solution was then treated with 1,1'-(azodicarbonyl) dipiperidine (7.56 g, 0.030 mol). The dark yellow reaction mixture was stirred at room temperature for 18h, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (10% EtOAc in hexane) to yield the phenyl ether product as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.77-1.90 (m, 1H), 1.95-2.23 (m, 3H),
2.74-2.85 (m, 1H), 2.88-2.97 (m, 1H), 5.50-5.53 (m, 1H), 7.09-7.60 (m, 7H),
7.84-7.89 (m, 1H), 9.90 (s, 1H).

Step B:

To a mixture of 4-(1,2,3,4-tetrahydro-1-naphthoxy)benzaldehyde (264 mg, 1.05 mmol) and 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (232 mg, 1.00 mmol) in 1,2-dichloroethane (15 mL) was added sodium triacetoxyborohydride (369 mg, 1.74 mmol). The resultant reaction mixture was stirred at room temperature under argon atmosphere for 20h. The reaction mixture was quenched with 1N aqueous NaHCO₃ and extracted with CHCl₃ (2 x 50 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated. The


crude product was purified by flash chromatography on silica gel (4% MeOH in CHCl₃) to yield the title product as an off-white solid.

MS (loop pos) MH⁺ = 468.2 (100%)

¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.60 (m, 2H), 1.70-1.80 (m, 1H), 5 1.85-2.05 (m, 3H), 2.50-2.65 (m, 2H), 2.70-2.85 (m, 6H), 3.45 (s, 2H), 4.55 (s, 2H), 5.45-5.45 (m, 1H), 6.75-6.80 (m, 1H), 6.85 - 6.90 (m, 2H), 7.00-7.05 (s, 2H), 7.15-7.35 (m, 8H), 8.60 (s, 1H).

Example 4

10 1-phenyl-8-[[2-(2-thiazolyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one
(Compound #24)



Step A:

To a mixture of 2-bromothiazole (826 mg, 4.99 mmol) and tetrakis(triphenylphosphine) palladium (0) (175 mg, 0.151 mmol) in 1,2-dimethoxyethane (20 mL) was added 2-formylbenzeneboronic acid (0.9017 g, 6.01 mmol) and 1N aqueous NaHCO₃ (8 mL). The resultant mixture was heated at reflux for 6 hrs. The reaction mixture was diluted with water and extracted with EtOAc (2 X 50 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated. The crude product was purified by gradient flash chromatography (10% to 25% EtOAc in hexane) to yield 2-(2-thiazolyl)benzaldehyde as a white solid.

MS (loop pos) MH⁺ = 190.1

¹H NMR (300 MHz, CDCl₃) 7.50 (m, 1H), 7.55-7.60 (m, 1H), 7.65-7.70 25 (m, 1H), 7.75-7.80 (m, 1H), 7.95-7.97 (m, 1H), 8.00-8.05 (m, 1H), 10.5 (s, 1H)

Step B:

To a mixture of 2-(2-thiazolyl)benzaldehyde (200 mg, 1.06 mmol) and 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (.232 mg, 1.00 mmol) in 1,2-dichloroethane (20 mL) was added sodium triacetoxyborohydride (376 mg, 1.79 mmol). The resultant mixture was stirred at room temperature for 18h, quenched with aqueous NaHCO₃ (50 mL) and extracted with CHCl₃ (2 x 50 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated. The crude product was dissolved in 1:1 CHCl₃:CH₃OH (30 mL) and treated with 2 mL of 1 N HCl in Et₂O. The HCl salt was precipitated by addition of Et₂O, collected by filtration and dried in the vacuum oven at 60°C for 18h to yield the product as an amorphous solid.


MS (loop pos): MH⁺ = 405.1 (100%)

¹H NMR (300 MHz, DMSO d₆) δ 1.50-1.60 (m, 2H), 2.75-2.90 (m, 2H), 3.45-3.55 (m, 2H), 3.75-3.90 (m, 2H), 4.65 (s, 2H), 4.70 (s, 2H), 6.76-6.81 (m, 1H), 6.95-6.98 (m, 2H), 7.18-7.24 (m, 2H), 7.60-7.70 (m, 2H), 7.90-7.99 (m, 3H), 8.14-8.15 (m, 1H), 9.00 (s, 1H), 9.80 (br s, 1H exchangeable).

Compounds 58 and 59 were similarly prepared according to the procedure above with selection and substitution of a suitable reagent for the 2-bromothiazole in Step A.

EXAMPLE 5

1-phenyl-8-[2-[2-(2-thienyl)phenyl]ethyl]-1,3,8-triazaspiro[4.5]decan-4-one
 (Compound #401)



5 Step A:

To a stirring mixture of 2-bromophenethyl alcohol (0.72 mL, 5.31 mmol) and tetrakis (triphenylphosphine) palladium (0) (620mg, 10 mol%) in 1,2-dimethoxyethane (45 mL) was added thiophene-2-boronic acid (2.0391 g, 0.0159 mol) and 1 N aqueous NaHCO₃ (15 mL). The resultant reaction mixture was heated at reflux for 66h under argon atmosphere. The dark reaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc (2 x 75 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated. The dark residue was purified by flash chromatography on silica gel (30% EtOAc in hexane) to yield 2-(2-thienyl)phenethyl alcohol as a light yellow oil.

¹H NMR (300 MHz, DMSO d₆) δ 2.87 (t, J=7.44, 7.43 Hz), 3.52-3.58 (m, 2H), 4.68 (t, J =5.17, 5.18 Hz, 1H (exchangeable)), 7.14-7.15 (m, 2H), 7.20-7.38 (m, 4H), 7.59-7.61 (m, 1H).

20 Step B:

To a cold (0°C) solution of 2-(2-thienyl)phenethyl alcohol (206 mg, 1.01 mmol) and triethylamine (170 μL, 1.22 mmol) in anhydrous CH₂Cl₂ (10 mL) was added methanesulfonyl chloride (94 μL, 1.21 mmol). Upon complete addition of the methanesulfonyl chloride, the reaction was stirred at room temperature

under argon atmosphere for 1h. The reaction mixture was then diluted with CH₂Cl₂ (50 mL), washed with H₂O (1x25 mL), aq NaHCO₃ (2x25 mL), dried over Na₂SO₄, filtered and concentrated to yield the mesylate compound as a yellow oil, which was taken into the next step without further purification.

5 ¹H NMR (300 MHz, CDCl₃) δ 2.81 (s, 3H), 3.22 (t, J= 7.12, 7.13 Hz, 2H),
4.30 (t, J= 7.13, 7.12 Hz), 7.02-7.04 (m, 1H), 7.08-7.12 (m, 1H), 7.27-7.41 (m,
5H).

Step C:

10 Crude mesylate compound prepared as in Step B (270 mg, ca 1.0 mmol), 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (197 mg , 0.852 mmol) and diisopropylethylamine (0.20 mL, 1.15 mmol) in 1-methyl-2-pyrrolidinone (5 mL) were stirred in an preheated oil bath (60°C) for 18h and at 85°C for 6h. The reaction mixture was diluted with aq NaCl and extracted with CHCl₃ (2x25 mL).

15 The organic solution with H₂O (6x 50 mL), dried over Na₂SO₄, filtered and concentrated. The crude oil was purified by flash chromatography (4% CH₃OH in CHCl₃) to yield an oil (256 mg) which contained N-methyl-2-pyrrolidinone. The crude product was dissolved in EtOAc (25 mL), and treated with 1 mL of 1 N HCl in Et₂O. The HCl salt was precipitated by addition of Et₂O, collected by

20 filtration and dried in the vacuum oven at 70°C for 1 day to yield the product as an amorphous off-white solid.


MS (loop pos): MH⁺ = 418.1 (100%)

1H NMR (300 MHz, DMSO d₆) δ 1.50-1.60 (m, 2H), 2.89-2.93 (m, 2H),
3.23-3.27 (m, 4H), 3.40-3.50 (m, 4H), 4.62 (s, 2H), 6.78-6.82 (m, 1H), 7.01-
25 7.05 (m, 2H), 7.18-7.29 (m, 4H), 7.33-7.43 (m, 3H), 7.47-7.50 (m, 1H), 7.68-
7.70 (m, 1H), 9.02 (s, 1H), 10.46 (br s, 1H exchangeable).

Compounds 402, 411 and 412 were similarly prepared according to the procedure described above with selection and substitution of a suitably substituted boronic acid for the thiophene-2-boronic acid in Step A.

EXAMPLE 6

8-[4-(1,2,3,4-tetrahydroquinolin-1-ylmethyl)-benzyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one (Compound # 218)



5 Step A:

A mixture of 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (2.3180 g, 0.010 mol), α,α -dichloro-p-xylene (5.2514 g, 0.030 mol) and diisopropylethylamine (1.484 g, 0.0114 mol) in 1-methyl-2-pyrrolidinone (45 mL) was stirred in a preheated oil bath (80°C) for 5h. The reaction mixture was diluted with H_2O (100 mL) and extracted with EtOAc (2 X 200 mL). The organic phase was washed with H_2O (7 X 100 mL), dried over Na_2SO_4 then filtered and concentrated. The crude beige solid was stirred in Et_2O (500 mL), and filtered. The filtrate was acidified with 1N HCl in Et_2O (12 mL) to yield the product as a HCl salt, which was collected by filtration as a white solid.

15 MS (loop pos) $\text{MH}^+ = 370.1$ (100%), 372.1 (33%)
 ^1H NMR (300 MHz, DMSO- d_6) δ 1.85 (d, $J = 14.86$ Hz, 2H), 2.91-2.96 (m, 2H), 3.35-3.50 (m, 2H), 3.64-3.68 (m, 2H), 4.36-4.38 (m, 2H), 4.60 (s, 2H), 4.80 (s, 2H), 6.77 (t, 7Hz, 7Hz, 1H), 7.04 (d, 8.38 Hz, 2H), 7.21 (t, 7.53, 7.53Hz, 2H), 7.53 (d, $J = 7.85$ Hz, 2H), 7.69 (d, $J = 7.55$ Hz, 2H), 9.00 (s, 1H), 20 10.73 (s, 1H)

Step B:

Benzyl chloride (0.3 mmol) was converted to its free base by partitioning HCl salt (125.5 mg) between CH_2Cl_2 and aqueous NaHCO_3 . A solution of this free base in CH_3CN (7 mL) was treated sequentially with 1,2,3,4-tetrahydroquinoline (0.045 mL, 0.36 mmol) and triethylamine (0.083 mL, 0.60


mmol) and then refluxed for 18h. The reaction mixture was then cooled to room temperature, then diluted with CH₂Cl₂ (7 mL) and basified with 3N aqueous NaOH. The organic layer was washed with H₂O (2X), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by chromatography 5 on the Biotage apparatus (5% MeOH in CH₂Cl₂) to yield the product as an amorphous solid.

MS (loop pos) MH⁺ = 467.4 (100%)

¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.60 (m, 2H), 2.55-2.60 (m, 2H), 2.65-2.75 (m, 6H), 2.80-2.85 (m, 2H), 3.50-3.55 (m+s, 4H), 3.65 (s, 2H), 4.55 10 (s, 2H), 6.80-6.85 (m, 2H), 6.95-7.00 (m, 1H), 7.05-7.10 (m, 4H), 7.20-7.25 (m, 2H), 7.30-7.35 (m, 4H), 8.65 (s, 1H).

EXAMPLE 7

15 8-(2-phenoxyethyl-benzyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
(Compound #16)



Step A:

To a cold (0°C) heterogenous mixture of unwashed 80% NaH in mineral oil (0.4641g, 0.0155 mol) in anhydrous THF (15 mL) was added phenol (1.4148 20 g, 0.0155 mol) in THF (15 mL). Upon complete evolution of H₂ gas, the resultant slightly cloudy solution was treated with α,α-dichloro-o-xylene (5.2503 g, 0.0299 mol) and stirred at room temperature for 4h. DMSO (2 mL) was then added to the reaction mixture, and then stirred for 18 h. The reaction mixture was quenched with aqueous NH₄Cl and extracted with EtOAc (100 mL). The 25 organic solution was washed with H₂O (4X), dried over Na₂SO₄, filtered and

concentrated. The crude colorless oil was gradiently chromatographed on silica gel with 100 % hexane to 10% hexane in EtOAc to yield a mixture of the monoether product and the diether byproduct. The mixture was carried forward without further purification.

5 ¹H NMR: (300 MHz, DMSO-d₆) δ 4.85 (s, 2H), 5.25 (s, 2H), 6.90-7.10
(m, 3H), 7.25-7.40 (m, 5H), 7.50-7.55 (m, 1H)


Step B:

A mixture of crude monoether (170 mg, 0.777 mmol),
10 diisopropylethylamine (0.16 mL, 0.918 mmol) and 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (179 mg, 0.777 mmol) in 2-methyl-1-pyrrolidinone (4 mL) was stirred in a preheated oil bath (80°C) for 4h. The reaction mixture was diluted with H₂O (50 mL), extracted with EtOAc (2 X 50 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated. The crude product
15 was purified by flash chromatography (4% MeOH in CHCl₃) and by tapered preparative TLC (50% EtOAc in hexane) to yield the title product as a white solid.

MS (loop pos) MH⁺ = 428.4 (100%)
16 ¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.60 (m, 2H), 2.45-2.55 (m, 2H),
2.65-2.75 (m, 4H), 3.60 (s, 2H), 4.55 (s, 2H), 5.40 (s, 2H), 6.65-6.75 (m, 1H),
6.80-6.85 (m, 2H), 6.85-6.90 (m, 1H), 7.05-7.10 (m, 4H), 7.25-7.35 (m, 5H),
7.50-7.55 (m, 1H), 8.65 (s, 1H).

EXAMPLE 8

8-[3-naphth-1-yloxymethyl]-benzyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one
 (Compound #112)




5 Step A:

To 80% NaH in mineral oil (18.3 mg, 0.61 mmol) in DMF (20 mL) was added 1-naphthol (86.3 mg, 0.599 mmol). The resultant homogenous solution was treated with benzyl chloride (184 mg, 0.50 mmol) and stirred at room temperature under argon atmosphere for 18h. The reaction was heated for 4h at 60°C, treated with additional 1-naphthol (36.5 mg) and NaH (11.1 mg) and then stirred overnight at 80°C. The reaction mixture was then diluted with aqueous NH₄Cl (20 mL) and extracted with EtOAc (2 X 20 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated. The crude product was purified by tapered prep TLC (1:1 EtOAc/hexane) to yield the product as an off-white solid.

MS (loop pos) MH⁺ = 478.4 (100%)

¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.60 (m, 2H), 2.45-2.55 (m, 2H), 2.65-2.75 (m, 4H), 3.55 (s, 2H), 4.55 (s, 2H), 5.30 (s, 2H), 6.70-6.75 (m, 1H), 6.80-6.85 (m, 2H), 7.00-7.05 (m, 1H), 7.20-7.25 (m, 2H), 7.30-7.50 (m, 8H), 7.85-7.90 (m, 1H), 8.20-8.25 (m, 1H), 8.60 (m, 1H).

EXAMPLE 9


8-(3-phenyloxymethyl-benzyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one
(Compound #101)

5 A mixture of 8-(3-chloromethyl-benzyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4one, prepared as in Example 8 above, (203 mg, 0.500 mmol), phenol (56.8 mg, 0.603 mmol), KI (83.1 mg, 0.500 mmol) and K₂CO₃ (174 mg, 1.26 mmol) in DMF was stirred at room temperature for 1 day. The reaction mixture was diluted with H₂O and a white solid precipitated. The solid was
10 collected by filtration, washed with H₂O and dried under house vacuum. The crude product was initially purified by flash chromatography (5% MeOH in CHCl₃) and by tapered prep TLC (5% MeOH in CHCl₃) to yield the title product as a white amorphous solid.

15 MS (loop pos) MH⁺ = 428.3 (100%)
 ¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.60 (m, 2H), 2.45-2.55 (m, 2H), 2.65-2.75 (m, 4H), 3.55 (s, 2H), 4.55 (s, 2H), 5.20 (s, 2H), 6.75-7.07 (m, 6H), 7.20-7.40 (m, 8H), 8.60 (m, 1H).

Example 10

1-(4-fluorophenyl)-8-[[2-(2-thienyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one (Compound #32)



5 Step A:

To a mixture of 2-bromobenzaldehyde (1.17 mL, 10.0 mmol) and 2.0 M aqueous sodium carbonate (75 mL) in DME (225 mL) were added thiophene-2-boronic acid (1.53 g, 12.0 mmol) and tetrakis(triphenylphosphine)palladium[0] (578 mg, 0.5 mmol). The mixture was heated to reflux under nitrogen for 16 hr.

10 The resulting solution was cooled, and the crude product was extracted from aqueous solution with ethyl acetate. The organic layer was dried over MgSO_4 , and the solvents were removed under vacuum. The crude product was purified on flash column with 25% DCM in hexane to yield 2-(2-thienyl)benzaldehyde.

15 Step B:

2-(2-furanyl)-benzaldehyde was similarly prepared with substitution of 2-furanyl-2-boronic acid for the thiophene-2-boronic acid in the process outlined in Step A above.

20 Step C:

2-(2-Thienyl)benzaldehyde from step A (445.0 mg, 2.36 mmol) was dissolved in anhydrous DCE (30.0 mL) and split into 30 portions. One portion was added to the solution of 1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one (56.8 mg, 0.228 mmol) in DMF (0.5 mL). To the mixture were then added 25 TMOF (0.5 mL) and acetic acid (0.05 mL). The reaction was shaken for 2 hr.

Sodium tri(acetoxy)borohydride (60.0 mg, 0.285 mmol) was then added, and the reaction was shaken for 16 hr. The reaction was quenched with 1.0 M of sodium hydroxide aqueous solution (0.5 mL) and the crude products were extracted from the aqueous layers with DCM. The organic solvents were then 5 removed under vacuum. The crude product was purified by the Gilson semi-preparative HPLC to yield the title product as a TFA salt. The HPLC method used gradient flow at 10 mL/min from 10% of acetonitrile (with 0.1% TFA) in water (with 0.1% TFA) to 90% acetonitrile in water (with 0.1% TFA) in 10 min.


10 Compounds 35, 38, 42, 43, 45, 46 and 47 were similarly prepared according to the procedures above with selection and substitution of a suitably substituted 1,3,8-triazaspiro[4.5]decan-4-one for the 1-(4-fluorophenyl)-1,3,8-triazaspiro[4,5]decan-4-one in Step C.

15 Compounds 48, 50, 51, 52, 53, 54, 55 and 56 were similarly prepared according to the procedures above reacting 2-(2-furanyl)-benzaldehyde and selection and substitution of a suitably substituted 1,3,8-triazaspiro[4.5]decan-4-one for 1-(4-fluorophenyl)-1,3,8-triazaspiro[4,5]decan-4-one in Step C.

20 Compounds 60, 61, 62, 63, 64, 66, 67, 68, 69 and 70 were similarly prepared according to the procedure above with selection and substitution of a suitable reagent for the 1-(4-fluorophenyl)-1,3,8-triazaspiro[4,5]decan-4-one in Step C.

Example 11

4-oxo-1-phenyl-8-[2-(2-thienyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decane-3-acetamide (Compound # 36)



5

Step A:

1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-one (6.8 g, 29.2 mmol) was dissolved in a mixed solvent of anhydrous DCE (100 mL) and NMP (50 mL).

To the solution were added 2-(2-thienyl)benzaldehyde (5.0 g, 26.6 mmol),
 10 prepared as in Example 10, step A, and acetic acid (1.5 mL). The reaction was stirred for 2 hr. Sodium triacetoxyborohydride (11.3 g, 53.1 mmol) was then added to the reaction mixture. The reaction mixture was stirred for 16 hr, and then stopped by adding saturated NH₄Cl aqueous solution (20 mL). The crude product was extracted from the aqueous layer with ethyl acetate, and the
 15 organic layer was dried over MgSO₄. The solvents were removed under vacuum, the resulting white solid was washed with ether and hexane, twice each, to yield the product.

Step B:


20 To a solution of the product from Step A (201 mg, 0.124 mmol) anhydrous NMP (10 mL) was added sodium hydride (7.4 mg, 0.186 mmol), and the reaction was stirred for 1 hr. The reaction was then split into 5 portions. One portion was added to a solution of 2-bromoacetamide (19.7 mg, 0.143

mmol) in NMP (2 mL) the reaction mixture was stirred for 16 hr, and then the reaction was stopped by adding water (2 mL). The product was extracted from the aqueous layer with DCM, the solvents were removed, and the residue purified by the Gilson semi-preparative HPLC to yield the product as a TFA salt. The HPLC method used gradient flow at 10 mL/min from 10% of acetonitrile (with 0.1% TFA) in water (with 0.1% TFA) to 90% acetonitrile in water (with 0.1% TFA) in 10 min.

Compounds 31, 33 and 40 were prepared similarly according to the procedure described above with selection and substitution of suitable alkyl bromides in Step B.

Example 12

15 4-oxo-1-phenyl-8-[[2-(2-thienyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decane-3-acetic acid (Compound #40)



Step A:

To a solution of the product prepared in Example 11, Step A (50 mg, 0.124 mmol) in anhydrous NMP (10 mL) was added sodium hydride (7.4 mg, 0.186 mmol), and the reaction was stirred for 1 hr. The reaction was added to a solution of t-butyl 2-bromoacetate (21.1 μ L, 0.143 mmol) in NMP (2 mL) to prepare the intermediate compound. The reaction mixture was stirred for 16 hrs and then stopped by adding water (2 mL). The product was extracted from

the aqueous layer by DCM, the solvents were removed, and the residue purified by the Gilson semi-preparative HPLC to yield the product as a TFA salt. The HPLC method was gradient flow at 10 mL/min from 10% of acetonitrile (with 0.1% TFA) in water (with 0.1% TFA) to 90% acetonitrile in 5 water (with 0.1% TFA) in 10 min.

Step B:

To the product prepared in Step A was added 50% TFA in DCM (3 mL), and the reaction was stirred for 3 hours. The solvents and TFA were removed 10 under vacuum to yield the product as a TFA salt.


Compound 39, was similarly prepared according to the procedure described above with substitution of 2-(2-bromoethoxy)-tetrahydro-2H-pyran in Step A, followed by the de-protection by TFA in Step B to yield the product as a 15 TFA salt.

Compound 34, was similarly prepared according to the procedure described above with substitution of N-(2-bromoethyl)-phthalimide in Step A to yield compound 44, followed by de-protection in Step B to yield the product.

20

Example 13

8-(2-chloro-4-methyl-1-phenyl-2,5-dihydro-1H-pyrazol-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Compound # 303)




1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-one (0.050 g, 0.216 mmol), 5-chloro-3-methyl-1-phenylpyrazole-4-carboxaldehyde (0.042 g, 0.216 mmol), and sodium triacetoxylborohydride (0.039 g, 0.216 mmol) were combined in dry 1,2-dichloroethane (10 mL). The reaction was stirred overnight at room temperature. The mixture was concentrated to about 1 mL and the residue was purified by preparative thin layer chromatography to yield the title compound as a white solid.

MS (loop pos): $MH^+ = 436.0$.

1H NMR (300 MHz, $CDCl_3$) δ 7.21-7.60 (10 H, m), 4.73 (2 H, s), 3.7 (2 H, s), 2.7-2.9 (6 H, m), 2.55 (3 H, s), 1.70 (2 H, d, $J = 14$ Hz).

Example 14

8-[2,3']bithienyl-2'methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Acetic Acid Salt (Compound #305)



15

Step A:

To a stirring solution of 3-bromo-thiophene-2-carbaldehyde (0.120 g, 0.6 mmol) and 2-thiopheneboronic acid (0.134 g, 0.75 mmol) in 1,2-dimethoxyethane(4.0 ml) under argon was added sodium bicarbonate solution (1.0 M, 3.0 ml). Tetrakis(triphenylphosphine) palladium (0) (0.022 g, 0.02 mmol) was then added to the reaction mixture. The solution was heated under reflux for 24 hrs, then was extracted with ethyl acetate three times. The combined organic layers were dried over $MgSO_4$. The solvent was evaporated to yield [2,3']bithiophenyl-2'-carbaldehyde as a colorless oil which was used directly in next step, without further purification.

Step B:


To a stirring solution of the crude product from step A were added 1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one (0.145 g, 0.6 mmol), acetic acid(0.2 ml) in THF (4.0 ml) and sodium triacetoxylborohydride (0.266 g, 1.2 mmol) and 5 the resulting reaction mixture stirred at room temperature overnight. The solution was filtered and purified via HPLC purification to yield the title compound as a white solid.

MS (loop pos): $MH^+ = 410.0$.

¹H NMR (300 MHz, DMSO d₆) δ 8.98 (s, 1H), 7.88(d, J=5 Hz, 1H), 7.70 10 (d, J=5 Hz, 1H), 7.38 (d, J=3Hz, 1H), 7.33(d, J=5Hz, 1H), 7.26-7.20(m, 3H), 6.92-6.82(m, 2H), 6.79(m, 1H), 4.75(s, 2H), 4.59(s, 2H), 3.61(m, 2H), 3.43(m, 2H), 2.73(m, 2H), 1.87(m, 2H).

Example 15

15 8-(2-methyl-4-thien-2-yl-2H-pyrazol-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Compound # 304)



Step A:

2-Methyl-4-thien-2-yl-2H-pyrazol-3-carbaldehyde was prepared 20 according to the process described in Step A of Example 14, with substitution of 2-bromo-2-methyl-2H-pyrazol-3-carbaldehyde for 3-bromo-thiophene-2-carbaldehyde. The product was used directly in the next step without purification.

25 Step B:

The title compound was prepared according to the process described in Step B of Example 14, with substitution of 2-methyl-4-thien-2-yl-2H-pyrazol-3-carbaldehyde for [2,3']bithiophenyl-2'-carbaldehyde:, to yield the title compound as white solid.

5 MS (loop pos): $MH^+ = 408.0$.


1H NMR (300 MHz, DMSO d_6) δ 9.00 (s, 1H), 8.14(s, 1H), 7.55 (d, $J=2$ Hz, 1H), 7.26-7.13 (m, 4H), 6.95(d, $J=5$ Hz, 2H), 6.81(m, 1H), 4.60(s, 2H), 4.47(s, 2H), 3.93(s, 3H), 3.69(m, 2H), 3.54(m, 2H), 2.80(m, 2H), 1.89(m, 2H).

10

Example 16

8-((2-tolyl)-pyridin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one

Acetic Acid Salt (Compound # 306)



Step A:

15 To a stirring solution of 2-bromopyridine(5.13 g, 3.2 mmol) in THF (90 ml) at -78 °C was slowly added lithium diisopropylamide (LDA) (2 M in THF, 17.9 ml, 3.6 mmol) and the resulting reaction mixture allowed to stir for three hours. To the reaction mixture was then slowly added DMF (9.49 g, 130 mmol) in THF (10 ml). The reaction mixture was stirred at -78 °C for 30 min, and was 20 then allowed to warm to room temperature. Water (100 mol) was added and then the reaction mixture was extracted with ethyl acetate three times. The combined organic layers were dried over $MgSO_4$. The solvent was removed and the resulting residue purified over silica gel chromatography eluted with hexane, to yield 2-bromo-pyridine-3-carbaldehyde as a white solid.

25 1H NMR (300 MHz, $CDCl_3$) δ ; 10.35(s, 1H), 8.58(dd, $J=2$ Hz, 5Hz, 1H), 8.18(dd, $J=2$ Hz, 6Hz, 1H), 7.44(dd, $J=5$ Hz, 6Hz, 1H).

Step B:

To a stirring solution of 2-bromo-pyridine-3-carbaldehyde(0.68 g, 3.6 mmol) were added 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (0.846 g, 3.6 mmol), and acetic acid(1.1 g, 18 mmol) in THF (40.0 ml) and sodium triacetoxyborohydride (1.55 g, 7.3 mmol) and the resulting reaction mixture stirred at room temperature overnight. Water (50 ml) was added and the reaction mixture solution was extracted with ethyl acetate three times. The combined organic layers were dried over MgSO₄. The solvent was removed and the resulting residue was purified over silica gel column eluted with methylene chloride (97%), methanol(2%), acetic acid(1%) and then with saturated sodium bicarbonate solution to yield 8-(2-bromo-pyridin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one as a white solid.

MS (loop pos): MH⁺ = 402.9.

¹H NMR (300 MHz, DMSO d₆) δ; 8.67(s, 1H), 8.30(m, 1H), 7.93(m, 1H), 7.49(m, 1H), 7.25(m, 2H), 6.88(m, 2H), 6.75(m, 1H), 4.58(s, 2H), 3.59(s, 2H), 2.90-2.53(m, 6H), 1.61(m, 2H).

Step C:


To a stirring solution of the compound prepared in Step B (0.050 g, 0.12 mmol) and *m*-tolylboronic acid (0.025 g, 0.18 mmol) in 1,2-dimethoxyethane (3.0 ml) under argon was added sodium bicarbonate solution (1.0 M, 0.3 ml). Tetrakis(triphenylphosphine) palladium (0) (0.007 g, 0.006 mmol) was then added to the reaction mixture. The solution was heated at 91°C for 24 hrs, the solvent was then evaporated and the resulting residue was purified over HPLC to yield the title compound as a white solid.

MS (loop pos): MH⁺ = 413.1.

¹H NMR (300 MHz, DMSO d₆) δ; 8.94(s, 1H), 8.74(m, 1H), 8.20(m, 1H), 7.58(m, 1H), 7.45-7.21(m, 6H), 6.90-6.79(m, 3H), 4.56(s, 2H), 4.46(s, 2H), 3.30(m, 4H), 2.66 (m, 2H), 2.30(s, 3H), 1.82(m, 2H).

Example 17

1-phenyl-8-(2-(3-thienyl)-6-fluorophenyl)methyl-1,3,8-triazaspiro[4.5]decan-4-



one (Compound # 503)

6-Chloro-2-fluorobenzaldehyde (0.100 g, 0.772 mmol), 3-thienylboronic acid (0.148 g, 1.16 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.018 g, 0.019 mmol), tri-*tert*-butylphosphine (.008 g, 0.039 mmol), and potassium fluoride (0.202 g, 3.37 mmol) were dissolved in dry dioxane (4 mL). The reaction mixture was heated to reflux overnight. The reaction mixture was cooled and filtered through a plug of silica, washing with acetone. The filtrate was concentrated and then dissolved in 1,2-dichloroethane (10 mL). Sodium triacetoxyborohydride (0.128 g, 0.849 mmol) and 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (0.165 g, 0.772 mmol) were then added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was then diluted with water (15 mL) and extracted with dichloromethane (3 x 10 mL). The separated organic layers were concentrated and the residue was purified by preparative thin layer chromatography (5% methanol in dichloromethane) to yield the title compound as a yellow amorphous solid.

MS (loop pos): $MH^+ = 422.0$


^{1}H NMR ($CDCl_3$) δ : 7.93 (1 H, s), 7.79 (1 H, s), 7.48 (1 H, d, $J = 4.7$ Hz), 7.37 (1 H, dd, $J = 4.8, 3.0$ Hz), 7.20-7.31 (3 H, m), 7.03 (1 H, t, $J = 8.0$ Hz), 6.80-6.90 (4 H, m), 4.74 (2 H, s), 3.52 (2 H, s), 2.63-2.96 (8 H, m), 1.71 (2 H, d, $J = 13.7$ Hz).

Compound 501, 502, 504 and 505 were similarly prepared according to the procedure described above with selection and substitution of a suitable boronic acid for the 3-thienyl boronic acid.

5

Example 18

8-(2-(2-Biphenyloxy)ethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one



(Compound # 406)


1-Phenyl-1,3,8-

triazaspiro[4.5]decan-4-one (0.250 g, 1.08 mmol), 2-chloroacetaldehyde (45% solution in water, 0.283 mg, 1.62 mmol) and sodium cyanoborohydride (0.103 g, 1.62 mmol) were combined in methanol (5 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated and the residue purified by column chromatography (5% methanol in dichloromethane). A portion of the resulting product (0.025 g, 0.085 mmol) was dissolved in dry dimethylformamide (1 mL). 2-Hydroxybiphenyl (0.029 g, 0.170 mmol) and potassium carbonate (0.059 g, 0.425 mmol) were then added. The reaction mixture was stirred at room temperature overnight, diluted with water (5 mL), and then extracted with dichloromethane (3 x 5 mL). The combined extracts were concentrated and the residue was purified by preparative thin layer chromatography (5% methanol in dichloromethane) to yield the title product as a white amorphous solid.

MS: 428.1 (M+1)

¹H NMR (CDCl₃) δ 7.58-7.60 (2 H, m), 7.24-7.39 (7 H, m), 7.00-7.06 (2 H, m), 6.83-6.91 (3 H, m), 6.39 (1 H, s), 4.72 (1 H, s), 4.12 (2 H, t, *J* = 5.7 Hz), 2.78-2.96 (6 H, m), 2.59-2.69 (2 H, m), 1.67 (2 H, d, *J* = 14.0 Hz).

Example 19

8-(2-phenoxy-benzyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one HCl Salt
(Compound # 57)

5

Step A: (Yaeger, et al. *Synthesis*, 1995, pp28)

To a solution of phenol (1.8888 g, 0.0201 mol) and 2-fluorobenzaldehyde (2.14 mL, 0.0203 mol) in N,N-dimethylacetamide (20 mL) was added anhydrous K₂CO₃ (3.0798 g, 0.0223 mol). The resulting heterogenous mixture 10 was refluxed for 3h. The resulting green mixture was then treated with H₂O (100 mL) and extracted with EtOAc (2x100 mL). The combined organic extracts were washed with H₂O (4x 100 mL), dried over Na₂SO₄, filtered and concentrated. The resulting dark residue was purified by flash chromatography on silica gel (10% EtOAc in hexane) to yield 2-phenoxybenzaldehyde as a light 15 yellow oil.

¹H NMR (300 MHz, DMSO d₆) δ 6.91 (m, 1H), 7.15 (m, 2H), 7.19- 7.25 (m, 2H), 7.45-7.55 (m, 2H), 7.65-7.70 (m, 1H), 7.85-7.90 (m, 1H).

Step B:

20 To a mixture of 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (291 mg, 1.26 mmol) and 2-phenoxybenzaldehyde (299 mg , 1.50 mmol) in 1,2-dichloroethane (25 mL) was added sodium triacetoxyborohydride (454 mg, 2.14 mmol). The resulting mixture was stirred at room temperature under nitrogen atmosphere for 20h. The reaction mixture was then quenched with 1N 25 aqueous NaHCO₃ and extracted with CHCl₃ (100 mL). The combined extracts were dried over Na₂SO₄, filtered and concentrated. The isolated solid was

purified by flash chromatography on silica gel to yield the title compound as a free base.


The free base was dissolved in CHCl₃ (35 mL), and treated with 2.5 mL of 1N HCl in Et₂O. The corresponding HCl salt was precipitated by addition of 5 Et₂O, then collected by filtration and dried the vacuum oven at 50 °C for 18h to yield the title product as an amorphous solid.

MS (loop pos): MH⁺ = 414.1 (100%).

¹H NMR (300 MHz, DMSO d₆) δ 1.85-1.95 (m, 1H), 2.90-3.10 (m, 2H), 3.35-3.60 (m, 2H), 3.70-3.85 (m, 2H), 4.35-4.45 (m, 2H), 4.60 (s, 2H), 7.05-10 7.20 (m, 4H), 7.25-7.35 (m, 4H, 7.45-7.55 (m, 3H), 7.85-7.90 (m, 1H), 9.00 (s, 1H), 10.9 (s, 1H)

Example 20

15 8-[3-(2-thiophen-2-yl-phenyl)-propyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
HCl Salt (Compound # 403)



Step A

Trimethylsilyldiazomethane (2M in hexanes, 5.0 mL, 10.0 mmol) was added to a solution of 3-(2-bromophenyl)propionic acid (1.376 g, 6.00 mmol) in 20 anhydrous benzene (28 mL) and anhydrous methanol (8 mL). The reaction mixture was stirred at room temperature for 2h, and then the volatiles were removed in vacuo, to yield crude methyl 3-(2-bromophenyl)propionate which was carried forward without further purification.

¹H NMR (300 MHz, DMSO d₆) δ 2.39 (t, 7.55, 7.55 Hz, 2H), 2.72 (t = 7.55, 7.55Hz, 2H), 3.36 (s, 3H), 6.89-6.96 (m, 1H), 7.05-7.14 (m, 2H), 7.34-7.37 (m, 1H).

5 Step B

To a mixture of the crude methyl 3-(2-bromophenyl)propionate (1.59 g, ca 0.006 mol) and tetrakis(triphenylphosphine) palladium (0) (695 mg, 0.601 mmol) in 1,2-dimethoxyethane (45 mL) were added thiophene-2-boronic acid (2.304 g, 0.018 mol) and 1N aqueous NaHCO₃ (15 mL). The resulting mixture 10 was heated at reflux under nitrogen atmosphere for 66 hrs. The dark reaction mixture was then diluted with water (100 mL) and extracted with EtOAc (2 X 100 mL). The combined organic layers were dried over Na₂SO₄, filtered and then concentrated. The resulting crude product was purified by flash chromatography (5% EtOAc in hexane) to yield methyl 2-(2-thienyl)phenylpropionate as a light green oil.

15 ¹H NMR (300 MHz, DMSO d₆) δ 2.50-2.56 (m, 2H), 2.95-2.98 (m, 2H), 3.55 (s, 3H), 7.14-7.17 (m, 2H), 7.27-7.35 (m, 4H), 7.61-7.63 (m, 1H).

Step C

20 To a cold (0°C) solution of methyl 2-(2-thienyl)phenylpropionate (387 mg, 1.57 mmol) and anhydrous lithium chloride (353 mg, 8.32 mmol) in an EtOH/THF mixture (4:3; 28 mL) was added sodium borohydride (315 mg, 8.32 mmol). The reaction mixture was then stirred at room temperature for 20 h. Aqueous NH₄Cl (50 mL) was added and the crude product was extracted with 25 EtOAc (2 x 50 mL). The organic layer was separated, dried over Na₂SO₄, filtered and concentrated. The resulting residue was purified by flash chromatography (5% EtOAc in hexane) to yield 2-(2-thienyl)phenpropyl alcohol as a light yellow oil.

30 ¹H NMR (300 MHz, DMSO d₆) δ 1.59-1.68 (m, 2H), 2.69-2.74 (m, 2H), 3.34-3.38 (t, J = 6.6, 6.6 Hz, 2H), 4.01-4.06 (br s, 1H), 7.12-7.34 (m, 6H), 7.59-7.61 (m, 1H).

Step D:

To a cold (0°C) solution of 2-(2-thienyl)phenpropyl alcohol (312 mg, 1.43 mmol) and triethylamine (250 µL, 1.79 mmol) in anhydrous CH₂Cl₂ (10 mL) was added methanesulfonyl chloride (120 µL, 1.55 mmol). Upon complete addition 5 of the methanesulfonyl chloride, the reaction was stirred at room temperature under argon atmosphere for 1h. The reaction mixture was then diluted with CH₂Cl₂ (75 mL), washed with H₂O (2x50 mL), aq NaHCO₃ (2x25 mL), dried over Na₂SO₄, filtered and concentrated to yield 3-(2-thien-2-yl-phenyl)-propyl ester methanesulfonic acid as a yellow oil, which was taken into the next step 10 without further purification.

¹H NMR (300 MHz, CDCl₃) δ 1.90-1.99 (m, 2H), 2.84-2.90 (m, 2H), 2.93 (s, 3H), 4.15 (t, J = 6.37, 6.37 Hz), 7.00-7.02 (m, 1H), 7.07-7.10 (m, 1H), 7.21-7.38. (m, 5H).

15 Step E:

The crude oil prepared in Step D (397 mg, 1.34 mmol), 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (295 mg, 1.28 mmol) and diisopropylethylamine (200 µL, 1.55 mmol) in 1-methyl-2-pyrrolidinone (4 mL) were stirred in an preheated oil bath (65°C) for 18h. The reaction mixture was diluted with aq 20 NaCl and extracted with EtOAc (2 x 40 mL). The organic solution was washed with H₂O (4x 50 mL), dried over Na₂SO₄, filtered and concentrated. The resulting crude product was purified by tapered preparative TLC (4% MeOH in CHCl₃) to furnish 239 mg of a beige solid. The free base was dissolved in CHCl₃ (25 mL), and then treated with 1 mL of 1N HCl in Et₂O. The HCl salt 25 was precipitated by addition of Et₂O, collected by filtration and dried in the vacuum oven at 60°C for 20h to yield the title product as an amorphous beige solid.

MS (loop pos): M⁺ = 432.1 (100%)


¹H NMR (300 MHz, DMSO d₆) δ 1.75–1.85 (m, 2H), 1.90-2.05 (m, 2H), 30 2.75-2.80 (m, 2H), 2.85 –2.95 (m, 2H), 2.95-3.10 (m, 2H), 3.40-3.60 (m, 4H), 4.62 (s, 2H), 6.78-6.82 (m, 1H), 7.01-7.05 (m, 2H), 7.18-7.43 (m, 8H), 7.60-7.70 (m, 1H), 9.02 (s, 1H), 10.46 (br s, 1H exchangeable).

Compound 404 was similarly prepared according to the procedure described above with substitution of thiophene-3-boronic acid for the thiophene-2-boronic acid in Step A.

5

Example 21

8-[4-(2-thiophen-2-yl-phenyl)-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
HCl Salt (Compound # 405)



10 Step A (Ref: Wolfe, et al; Tetrahedron, 1996, 52(21), 7525):
 To an ice cold solution of 2-bromobenzyl bromide (5.00 g, 0.020 mol) in THF (25 mL) was added 1M allyl magnesium bromide (100 mL, 0.100 mol) slowly via cannula. The reaction mixture was stirred at reflux for 1.5h, cooled in an ice bath and quenched with 50 mL of aqueous 2M H₂SO₄. Water (50 mL)
 15 was added to dissolve any remaining solid and the layers were separated. The aqueous layer was extracted with Et₂O (2 x 150 mL). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated to yield 1-bromo-2-but-3-enyl-benzene as a light yellow oil. The isolated crude product was carried forward without further purification.
 20 ¹H NMR (300 MHz, CDCl₃) δ 2.33-2.40 (m, 2H), 2.80-2.85 (m, 2H), 4.98-5.17 (m, 2H), 5.81-5.94 (m, 1H), 7.02-7.08 (m, 1H), 7.19-7.27 (m, 2H), 7.51-7.54 (m, 1H).

Step B:

To a solution of 0.4 M 9-BBN in hexane (72mL, 28.8 mmol) was added 4-bromophenyl-1-butene (3.99 g, 18.9 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20h. The mixture was
5 treated sequentially with 3.3 mL of 6N aqueous NaOH (19.8 mmol), THF (7 mL), and 30% H₂O₂ in H₂O (7 mL), then refluxed for 2h. The reaction mixture was then cooled to room temperature. The organic layer was washed with aqueous sodium sulfite (40 mL), H₂O (20 mL), and brine (20 mL). The aqueous extracts were combined, saturated with solid K₂CO₃ and extracted
10 with Et₂O (3x50 mL). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated. The resulting crude product was purified by flash chromatography twice (33% EtOAc in hexane and 20% EtOAc in hexane) to yield 4-(o-bromophenyl)butanol).

15 ¹H NMR (300 MHz, DMSO-d₆) δ 1.41-1.64 (m, 4H), 2.69 (t, = 7.28, 7.61 Hz, 2H), 3.42 (t, J = 6.40, 6.41 Hz, 2H), 4.40 (br s, 1H), 7.10-7.16 (m, 1H), 7.30-7.33 (m, 2H), 7.55-7.57 (m, 1H).

Step C:

To a solution of 4-(o-bromophenyl)-1-butanol (1.222 g, ca 0.0053 mol)
20 and tetrakis(triphenylphosphine) palladium (0) (650 mg, 0.562 mmol) in 1,2-dimethoxyethane (55 mL) was added thiophene-2-boronic acid (2.057 g, 0.016 mol) and 1N aqueous NaHCO₃ (15 mL). The resulting mixture was heated at reflux under nitrogen atmosphere for 3 days. The dark reaction mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL). The organic
25 layer was dried over Na₂SO₄, filtered through a bed of Celite and concentrated to yield a crude which was purified by flash chromatography (30% EtOAc in hexane) to yield 4-(2-thien-2-yl-phenyl)-butan-1-ol as a light brown oil.

30 ¹H NMR (300 MHz, DMSO d₆) δ 1.37-1.56 (m, 4H), 2.66-2.71 (m, 2H), 3.31-3.35 (m, 2H), 4.33 (br s, 1H), 7.10-7.15 (m, 2H), 7.21-7.26 (m, 1H), 7.31-7.34 (m, 3H), 7.59-7.61 (m, 1H).

Step D:

To a cold (0°C) solution of 2-(2-thienyl)phenylbutanol (1.149 g, 0.00495 mmol) and triethylamine (0.87 mL, 6.24 mmol) in anhydrous CH₂Cl₂ (40 mL) was added methanesulfonyl chloride (0.48 mL, 6.20 mmol). Upon complete addition of the methanesulfonyl chloride, the reaction was stirred at room

5 temperature under argon atmosphere for 1.5 h. The reaction mixture was then diluted with CH₂Cl₂ (50 mL), washed with H₂O (3x50 mL), dried over Na₂SO₄, filtered and concentrated to yield crude 4-(2-thien-2-yl-phenyl)-butyl ester methane sulfonic acid as a brown oil, which was taken into the next step without further purification.

10 ¹H NMR (300 MHz, CDCl₃) δ 1.66-1.76 (m, 4H), 2.77 (t, J = 7.1, 7.4 Hz, 2H), 2.94 (s, 3H), 4.15 (t, J= 6.08, 6.08 Hz), 7.00-7.02 (m, 1H), 7.07-7.10 (m, 1H), 7.25-7.35. (m, 5H).

Step E:

15 The crude oil from Step D (390 mg, 1.24 mmol), 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (231 mg, 1.00 mmol) and diisopropylethylamine (210 μL, 1.20 mmol) in 1-methyl-2-pyrrolidinone (2.5 mL) were stirred in an preheated oil bath (70°C) for 20h. The reaction mixture was diluted with aq NaCl (25 mL) and extracted with EtOAc (2 x 20 mL). The organic layer was

20 washed with H₂O (4x 50 mL), dried over Na₂SO₄, filtered and concentrated to yield a crude oil, which was purified by flash chromatography (5% CH₃OH in CHCl₃) to yield the title compound as a free base, as an oil (218 mg). The free base was dissolved in CHCl₃ (15 mL), and treated with 1 mL of 1N HCl in Et₂O. The HCl salt was precipitated by addition of Et₂O, collected by filtration and

25 dried in the vacuum oven at 50°C for 20h to yield the title product as an amorphous beige solid.

MS (loop pos): MH⁺ = 446.1 (100%)

1H NMR (300 MHz, DMSO d₆) δ 1.75-1.85 (m, 2H), 1.90-2.05 (m, 2H), 2.75-2.80 (m, 2H), 2.85 –2.95 (m, 2H), 2.95-3.10 (m, 2H), 3.40-3.60 (m, 4H),


30 4.62 (s, 2H), 6.80-6.90 (m, 1H), 7.01-7.05 (m, 2H), 7.18-7.43 (m, 8H), 7.60-7.65 (m, 1H), 9.00 (s, 1H), 10.60 (br s, 1H exchangeable).

Compound 506 was similarly prepared according to the procedure described above with substitution of 1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one for the 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one in Step E.

5

Example 22

5-[4-oxo-1-phenyl-8-(2-thionphen-3-yl-benzyl)-1,3,8-triazaspiro[4.5]dec-3-ylmethyl]-oxazole-4-carboxylic acid methyl ester HCl Salt (Compound # 65)



10 Step A:

To a cold (0 °C) mixture of Boc 3-carboxymethyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (3.893 g, 0.010 mol), and potassium carbonate sesquihydrate (6.606 g, 0.040 mol) in DMF (20 mL) was added diphenylphosphoryl azide (3.03 mL, 14.0 mmol) and methyl isocyanoacetate (1.9 mL, 20.9 mmol). The reaction mixture was stirred for 1 day at room temperature. The reaction was then diluted with aq NaCl and extracted with CHCl₃ (150 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated to a brown oil. The crude product was purified by flash chromatography twice (2% MeOH in CHCl₃) to yield 3-(4-methoxycarbonyl-oxazol-5-ylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-carboxylic acid-*t*-butyl ester as a tacky solid.

¹H NMR (300 MHz, CDCl₃) δ 1.50 (s, 9H), 1.62-1.66 (m, 2H), 2.40-2.60 (m, 2H), 3.50-3.65 (m, 2H), 3.98 (s, 3H), 3.98-4.18 (m, 2H), 5.07 (s, 2H), 6.72-6.75 (m, 2H), 6.85-6.90 (m, 1H), 7.21-7.24 (m, 2H), 7.89 (s, 1H).

5 Step B:

To a solution of the solid prepared in Step A (1.9457 g, 0.00414 mol) in DCM (35 mL) was added CF₃CO₂H (15 mL). The reaction mixture was then stirred for 1.5h and concentrated in vacuo. The residue was treated with aqueous NaHCO₃ and product was extracted into CHCl₃ (2x 75 mL). The 10 organic extracts were dried over Na₂SO₄, filtered and concentrated to yield an oil. The oil (the free base of 1-phenyl-3-(4-methoxycarbonyl-oxazol-5-ylmethyl)-1,3,8-triazaspiro[4.5]decan-4-one) was dissolved in EtOAc (30 mL), and treated with 7 mL of 1N HCl in Et₂O. The HCl salt was precipitated by addition of Et₂O, collected by filtration and dried in the vacuum oven at 50°C for 15 20h to yield an amorphous beige solid.

MS (loop pos): MH⁺ = 371.1 (100%).

¹H NMR (300 MHz, DMSO d₆) δ 1.75-1.85 (m, 2H), 2.45-2.55 (m, 2H), 3.30-3.40 (m, 2H), 3.45-3.60 (m, 2H), 3.85 (s, 3H), 4.70 (s, 2H), 4.95 (s, 2H), 6.75-6.85 (m, 1H), 6.90-7.00 (m, 2H), 7.20-7.25 (m, 2H), 8.45 (s, 1H), 8.90-20 9.20 (m, 2H- exchangeable).

Step C:

A heterogenous mixture of 2-(2-thienyl)benzaldehyde (206 mg 1.09 mmol), the HCl salt prepared in Step B (406 mg, 1.00 mmol) and triethylamine 25 (0.21 mL, 1.50 mmol) in 1,2-dichloroethane (10 mL) was stirred for 0.5 h, treated with sodium triacetoxyborohydride (372 mg, 1.76 mmol) and the resulting mixture stirred for 1.5 days. The reaction mixture was then quenched with 1N aqueous NaHCO₃ and extracted with CHCl₃ (2x50 mL). The combined extracts were dried over Na₂SO₄, filtered and concentrated to yield a solid. 30 The isolated solid was purified by flash chromatography on silica gel (3% MeOH in CHCl₃) to yield 1-phenyl-3-(4-methoxycarbonyl-oxazol-5-ylmethyl)-8-(2-thien-2-yl-phneylmethyl)-1,3,8-triazasprio[4.5]decan-4-one as a free base. The free base (180 mg) was dissolved in EtOAc (25 mL) and treated with 0.7

mL of 1N HCl in Et₂O. HCl salt was precipitated by addition of Et₂O, collected by filtration and dried the vacuum oven at 50°C for 18 h to yield the title compound as an amorphous solid.


MS (loop pos): MH⁺ = 543.6 (100%).

5 ¹H NMR (300 MHz, DMSO d₆) δ 1.75-1.85 (m, 2H), 2.45-2.55 (m, 2H), 3.30-3.40 (m, 2H), 3.45-3.60 (m, 2H), 3.85 (s, 3H), 4.70 (s, 2H), 4.95 (s, 2H), 6.70-6.80 (m, 1H), 6.90-7.00 (m, 2H), 7.15-7.25 (m, 4H), 7.45-7.60 (m, 3H), 7.70-7.75 (m, 1H), 8.15-8.20 (m, 1H), 8.45 (s, 1H), 10.9 (br s, 1H-exchangeable).

10

Example 23

3-(2-dimethylamino-ethyl)-1-phenyl-8-[2-(2-thienen-2-yl-phenyl)-ethyl]-1,3,8-triazaspiro[4.5]decan-4-one HCl Salt (Compound # 407)



15 To a heterogenous mixture of unwashed 60% NaH dispersed in mineral oil (96.5 mg, 2.41 mmol) in DMF (3 mL) was added 8-[2-[2-(2-thienen-2-yl-phenyl)]ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (prepared as in Example 5) (208.8 mg, 0.500 mmol). The mixture was stirred until H₂ gas evolution was observed to stop (30 min), then treated with N,N-dimethylaminoethyl chloride hydrochloride (158 mg, 1.10 mmol). The resulting reaction mixture was stirred for an additional 18h under argon atmosphere.

20

The reaction was quenched with aqueous NH₄Cl (50 mL), and the crude product was extracted into CHCl₃ (2x40 mL). The organic extracts were washed with H₂O (5x 50 mL), dried over Na₂SO₄, filtered and concentrated to a crude oil. The crude oil was washed with hexane (3x50 mL) to remove mineral oil, then purified by Tapered prep TLC (6% MeOH in CHCl₃) to yield title compound as a free base. The free base was dissolved in CHCl₃ (15 mL) and treated with 1.0 mL of 1N HCl in Et₂O. HCl salt was precipitated by addition of Et₂O, collected by filtration and dried in the vacuum oven at 60°C for 18 h to yield the title compound as a white amorphous solid.

10 MS (loop pos): MH⁺ = 498.2 (100%)

1H NMR (300 MHz, DMSO d₆) δ 2.05-2.15 (m, 2H), 2.75 (s, 6H), 2.80-2.95 (m, 2H), 3.25 (s, 2H), 3.30-3.45 (m, 4H), 3.50-3.65 (m, 4H), 3.65-3.75 (m, 2H), 4.75 (s, 2H), 6.78-6.82 (m, 1H), 7.01-7.05 (m, 2H), 7.18-7.29 (m, 4H), 7.33-7.43 (m, 3H), 7.66-7.68 (m, 1H), 9.02 (s, 1H), 10.70 (br s, 1H exchangeable), 10.90 (br s, 1H exchangeable).

15 Compounds 408, 409 and 410 were similarly prepared according to the procedure described above with selection and substitution of a suitably substituted reagent for the N,N-dimethylaminoethyl chloride hydrochloride.

20

EXAMPLE 24

Method for measuring affinity for the ORL-1 receptor

25 The nociceptin receptor binding assay measures the binding of ¹²⁵I-Tyr¹⁴-nociceptin (2200 Ci/mmol, New England Nuclear) to human nociceptin receptor (ORL-1) on HEK293 cell membranes.

HEK293 cell membrane (prepared as described in Pulito, V.L. *et al.*, 2000, *J. Pharmacol. Exp. Ther.* 294, 224-229), with the exception that the buffer used was a mixture of 50 mM Tris-Cl pH7.8, 5 mM MgCl₂ and 1 mM EGTA), was added to PEI treated WGA FlashPlates (New England Nuclear) at 1 µg/well in binding buffer of 50 mM Tris- Cl pH 7.8, 5 mM MgCl₂ and 1 mM EGTA. ¹²⁵I-Tyr¹⁴-nociceptin was added at a final concentration of 0.5 nM and the volume adjusted to 50 µl with binding buffer. The plate was incubated for

two hours at room temperature, the reactions were aspirated and the wells washed two times with 200 μ l binding buffer and then filled with 200 μ l binding buffer. The plates were then sealed and counted on a Packard Top Count to determine radioactivity bound to the membranes.

5

For each test compound, the total binding (%Inh) was measured at several concentrations and the IC₅₀ (the concentration at which 50% of the binding is inhibited) was determined from the graphical display of X = logarithm of concentration versus Y = response, using the following calculation:

10

$$Y = \frac{(\text{Minimum}) + (\text{Maximum}-\text{Minimum})}{(1+10^{\log(\text{EC}_{50})-X})}$$

The ability of selected compounds of the present invention to bind to the ORL-1 receptor in a HEK cell line using a radio-labelled nociceptin as the displaceable ligand was determined according to the procedure described above with results as listed in Table 11.

15

TABLE 11

Cmpd #	IC ₅₀ (μ M)	% Inh @ 100 μ M	% Inh @ 10 μ M
1	0.024		
2	0.012		
3	0.960		
4	0.190		
5	0.305		
6	0.058		
7	0.271		
8	0.005		
9	0.006		
10	0.007		
11	0.054		
12	>10	insoluble	insoluble
13	0.759		

14	0.866		
15	>10	31	28
16	0.603		
17	>10	19.5	24
18	1.3		
19	>10	22	14.5
20	>10	25	15.5
21	>10	47	43
22	1.100		
23	0.158		
24	0.032		
25	0.201		
26	3.200		
27	0.378		
28	1.300		
29	0.047		
30	2.700		
31	0.0025		
32	0.0082		
33	0.0080		
34	0.0312		
35	0.0048		
36	0.0024		
38	0.0057		
39	0.0011		
40	0.0010		
41	0.0084		
48	0.0031		
49	0.0012		
50	0.0081		
51	0.0026		
52	0.0201		

53	0.0303		
57	0.0085		
58	0.524		
59	>10		
60	0.061		
61	0.109		
62	0.025		
63	0.016		
64	2.38		
65	0.0072		
66	0.048		
67	0.155		
68	0.023		
69	0.043		
70	1.59		
101	0.348		
102	0.632		
103	0.608		
104	0.244		
105	0.761		
106	4.100		
107	0.264		
108	0.574		
109	1.110		
110	0.346		
111	0.786		
112	0.241		
113	0.750		
114	0.339		
115	2.700		
116	2.200		
117	3.49		52

118	0.83		
119	>10		33
120	>10		11
121	>10		28
122	1.7		
123	1.23		
124	0.61		
125	0.34		
201	>10		13
202	0.388		
203	0.484		
204	0.252		
205	0.362		
206	1.140		
207	0.258		
208	0.383		
209	0.194		
210	0.223		
211	>10		30
213	>10		0
214	>10		16
215	>10		17
216	1.9		
217	1.8		
218	1.63		
301	0.433		
302	0.133		
303	4.75		
304	0.300		
305	0.011		
306	0.593		
401	0.009		

402	0.0076		
403	0.003		
404	0.011		
405	0.11		
406	0.94		
407	0.014		
408	0.022		
409	0.012		
410	0.079		
411	0.338		
412	0.790		
501	0.021		
502	1.3	64	
503	0.013		
504	0.006		
505	0.008		
506	0.74		

Example 25

In Vivo Acute Pain / Mouse Abdominal Irritant Test (MAIT)

5 The procedure used in detecting and comparing the analgesic activity of test compounds for which there is a good correlation with human efficacy is the prevention of acetylcholine-induced abdominal constriction in mice (H. Collier, et al., *Br. J. Pharmacol.*, 1968, 32, 295).

10 More specifically, male CD1 mice (weighing from 18-24 g) are utilized in determining the analgesic effect of test compounds. The mice are dosed orally with test compound dissolved in distilled water or dissolved in a suspension of 0.5% hydroxypropyl methylcellulose in distilled water. The dosing volume is 2 mL/kg.

15

The mice are injected intraperitoneally with a challenge dose of acetylcholine bromide. The acetylcholine is completely dissolved in distilled water at a concentration of 5.5 mg/kg and injected at the rate of 0.20 mL/20 g. For scoring purposes, an "abdominal constriction" is defined as a contraction of the abdominal musculature accompanied by arching of the back and extension of the limbs. The mice are observed for 10 minutes for the presence or absence of the abdominal constriction response beginning immediately after receiving the acetylcholine dose, administered at a certain time after the oral administration of test compound. Each mouse is used only once.

10

The absence of the abdominal constriction response is interpreted as efficacy of the test compound in controlling acute pain.

Example 26

15

In Vivo Study - Carrageenan Paw Hyperalgesia Test

The procedure used in detecting and comparing the antiinflammatory activity of test compounds is the carrageenan paw hyperalgesia test (Dirig, et al., *J. Pharmacol. Expt. Therap.*, 1998, 285, 1031).

20

More specifically, male, Sprague-Dawley rats (Charles River Laboratories) are housed in a climate-controlled, virus free environment for at least 5 days prior to testing. Food and water are available *ad libitum* up to test time.

25

Test rats are immunized by injecting an irritant (e.g., 0.1 ml of a 0.3-1.0% carrageenan solution in 0.9% saline) subcutaneously into the subplantar tissue of one of the hind paws to stimulate an acute inflammatory reaction. Control rats receive a similar saline injection.

30

The rats are dosed orally with test compound or vehicle, dissolved in either distilled water or dissolved in a suspension of 0.5% hydroxypropyl methylcellulose in distilled water at a fixed time following carrageenan injection.

The dosing volume is 2 mL/kg. The hyperalgesic response of the animal is subsequently evaluated at a fixed later time.

Hyperalgesia is assessed by measurement of a response to a thermal or a mechanical stimulus. Measurement of thermal hyperalgesia is made with a standard laboratory hot plate apparatus, whose surface temperature is precisely determined and evenly maintained. Alternatively, hyperalgesia is evaluated with a commercially available Hargreaves apparatus which selectively elevates the temperature of an individual paw (Dirig, et al., *J. Neurosci. Methods*, 1997, 76, 183). With either apparatus, hyperalgesia is measured as a reduced latency to response compared to the latency of an untreated or vehicle treated animal, and the analgesic effect of the test compound is seen as a (partial) restoration of the latency toward normal (Dirig, et al., *J. Pharmacol. Expt. Therap.*, 1998, 285, 1031). A response is defined as any shaking, licking, or tucking of the treated paw.

Assessment of hyperalgesia by a mechanical means is effected with a device designed to apply a precisely calibrated force to the paw. Hyperalgesia is measured as reduction in the force, measured in grams, needed to elicit paw withdrawal or vocalization (Randall and Selitto, *Arch. Int. Pharmacodyn.*, 1957, 4, 409). The analgesic effect of the test compound is seen as a (partial) restoration of the force eliciting a response toward normal.

Example 27

25 In Vivo Study - Open Space Trait Anxiety (Elevated Plus-Maze or EPM)

This behavioral assay is based on an innate behavior of the animal and may model human anxiety traits. Specifically, this test is based on the innate fear or aversion that rats have of illuminated open spaces. Compounds with anxiolytic activity have been shown to increase the frequency with which rats venture into open spaces and to increase the time the animal spends in the open arm of the EPM (Pellow et al., 1985).

Method:

Test compound or vehicle is administered orally to adult rats that have been deprived of food but not water for 18 h before use. At a specified time after dosing, the rats are placed on an open arm of the elevated plus-maze (p-maze), facing the center. The 10-min test is initiated when the rat enters the 5 center of the apparatus. Each black plastic maze has two open arms and two arms with 40 cm high walls (enclosed arms) of equal length (50 cm) extending from the center at right angles, such that arms of similar type are opposite each other. Each p-maze is elevated approximately 60 cm above the floor. Infrared photo-beams that crossed the entrance of each arm and the center of 10 the maze detected the exploratory activity of an animal. Data collection is automated.


The effectiveness of a test compound is determined by the number of entries into open versus enclosed arms and the duration of time spent in each 15 type of arm. Increased entry and time within open arms is interpreted as decreased anxiety and thus an indication of the effectiveness of a test compound as an anxiolytic.

(Pellow S, Chopin P, File SE and Briley M (1985) Validation of open-closed 20 arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J Neurosci Methods* 14: 149-167.)

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual 25 variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

What is claimed is:

1. A compound of the formula



wherein

5 R¹ is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl and aralkyl;

 wherein the aryl or aralkyl group is optionally substituted with one to four substituents independently selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl or C₃₋₈cycloalkyl;

10 R² is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, hydroxyaminoC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, aryl, C₃₋₈cycloalkyl, partially unsaturated carbocyclyl, heteroaryl, heterocycloalkyl, C₁₋₆aralkyl, carbocyclylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocycloalkylC₁₋₆alkyl and phthalimidoylC₁₋₆alkyl;

15 wherein the alkyl group is optionally substituted with one to two substituents independently selected from hydroxy, carboxy, cyano, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, hydroxyC₁₋₆alkylamino, aminoC₁₋₆alkylamino, C₁₋₆alkylaminoC₁₋₆alkylamino or di(C₁₋₆alkyl)aminoC₁₋₆alkylamino,

20 wherein the aryl, cycloalkyl, carbocyclyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently

selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl or C₁₋₄alkoxycarbonyl;

5 a is an integer from 0 to 2;

R³ is selected from the group consisting of C₁₋₄alkyl and hydroxy C₁₋₄alkyl;

n is an integer from 0 to 1;

X is selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₄alkyl-10 O and C₂₋₄alkyl-S;

wherein the alkyl group is optionally substituted with one to two substituents independently selected from fluoro, C₁₋₆alkyl, fluorinated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl or di(C₁₋₆alkyl)aminosulfonyl;

15 and wherein X is C₂₋₄alkyl-O or C₂₋₄alkyl-S, the X group is incorporated into the molecule such that the C₂₋₄alkyl is bound directly to the piperidine portion of the molecule;



is selected from the group consisting of phenyl, a five

20 membered heteroaryl and a six membered heteroaryl;

b is an integer from 0 to 1;

R⁴ is selected from the group consisting of aryl, C₃₋₈cycloalkyl, partially unsaturated carbocyclyl, heteroaryl and heterocycloalkyl;

c is an integer from 0 to 3;

25 R⁵ is selected from the group consisting of halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl or di(C₁₋₆alkyl)aminosulfonyl;

m is an integer from 0 to 1;

30 Y is selected from the group consisting of C₁₋₄alkyl, C₂₋₄alkenyl, O, S, NH, N(C₁₋₄alkyl), C₁₋₆alkyl-O, C₁₋₆alkyl-S, O-C₁₋₆alkyl and S-C₁₋₆alkyl-S;

R^6 is selected from the group consisting of aryl, partially unsaturated carbocyclyl, C₃₋₈cycloalkyl, heteroaryl, heterocycloalkyl and benzyloxyphenyl; wherein the aryl, partially unsaturated carbocyclyl, C₃₋₈cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently selected from halogen, hydroxy, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl or triphenylmethyl;

10 provided that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X is CH₂,



is phenyl, b is 0, c is 0 and m is 0, then R⁶ is selected from the group consisting of partially unsaturated carbocyclyl, C₃₋₈cycloalkyl, heteroaryl, heterocycloalkyl, benzyloxyphenyl and substituted aryl;

wherein the aryl, partially unsaturated carbocyclyl, C₃₋₈cycloalkyl,

15 heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl or

20 triphenylmethyl;

provided further that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X



is C₁₋₃alkyl, is phenyl, b is 0, c is 0 and m is 0, then R⁶ is not substituted thiazolyl; wherein the substituent on the thiazolyl is selected from amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino or nitro;

25 provided further that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X



is CH₂, b is 0, c is 0 and m is 0, and R⁶ is phenyl, then is not imidazolyl or pyrrolyl;

and pharmaceutically acceptable salts thereof.

2. A compound as in Claim 1 wherein
 R^1 is selected from the group consisting of C_{1-4} alkyl, aryl and aralkyl; wherein the aryl or aralkyl group is optionally substituted with one to three substituents independently selected from halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy, amino, (C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino, amido, (C_{1-4} alkyl)amido, di(C_{1-4} alkyl)amido or C_{5-7} cycloalkyl;
- 5 R^2 is selected from the group consisting of hydrogen, C_{1-4} alkyl, hydroxyamino C_{1-4} alkyl, aminocarbonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, aryl, C_{5-7} cycloalkyl, heteroaryl, heterocycloalkyl, C_{1-4} aralkyl, heteroaryl C_{1-4} alkyl, heterocycloalkyl C_{1-4} alkyl and phthalimidoyl C_{1-4} alkyl; wherein the alkyl group is optionally substituted with one to two substituents independently selected from hydroxy, carboxy, cyano, amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, hydroxy C_{1-4} alkylamino, amino C_{1-4} alkylamino, C_{1-4} alkylamino C_{1-4} alkylamino or di(C_{1-4} alkyl)amino C_{1-6} alkylamino, wherein the aryl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to two substituents independently selected from halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy, amino, (C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino, amido, (C_{1-4} alkyl)amido, di(C_{1-4} alkyl)amido or C_{1-4} alkoxycarbonyl;
- 10 20 a is an integer from 0 to 1;
- 15 R^3 is selected from the group consisting of C_{1-4} alkyl and hydroxy C_{1-4} alkyl; n is an integer from 0 to 1;
- 20 25 X is selected from the group consisting of C_{1-6} alkyl, C_{2-4} alkyl-O and C_{2-4} alkyl-S; wherein the alkyl group is optionally substituted with one to two substituents independently selected from fluoro, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy, amino, (C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino;
- 25 30 and wherein X is C_{2-4} alkyl-O or C_{2-4} alkyl-S, the X group is incorporated into the molecule such that the C_{2-4} alkyl is bound directly to the piperidine portion of the molecule;

(A)

is selected from the group consisting of phenyl, a five membered heteroaryl and a six membered heteroaryl;

b is an integer from 0 to 1;

R⁴ is selected from the group consisting of aryl, C₅-₇cycloalkyl, heteroaryl
5 and heterocycloalkyl;

c is an integer from 0 to 2;

R⁵ is selected from the group consisting of halogen, C₁-₄alkyl,
fluorinatedC₁-₄alkyl, C₁-₄alkoxy, nitro, amino, (C₁-₄alkyl)amino, di(C₁-₄alkyl)amino,
10 C₁-₄alkylsulfonyl, amido, (C₁-₄alkyl)amido, di(C₁-₄alkyl)amido,
sulfonyl, aminosulfonyl, (C₁-₄alkyl)aminosulfonyl or di(C₁-₄alkyl)aminosulfonyl;

m is an integer from 0 to 1;

Y is selected from the group consisting of C₁-₄alkyl, C₂-₄alkenyl, O, S,
NH, N(C₁-₄alkyl), C₁-₆alkyl-O, C₁-₆alkyl-S, O-C₁-₆alkyl and S-C₁-₆alkyl-S;

R⁶ is selected from the group consisting of aryl, partially unsaturated
15 carbocyclyl, C₃-₈cycloalkyl, heteroaryl, heterocycloalkyl and benzyloxyphenyl;
wherein the aryl, partially unsaturated carbocyclyl, C₃-₈cycloalkyl,
heteroaryl or heterocycloalkyl group is optionally substituted with one to two
substituents independently selected from halogen, hydroxy, C₁-₄alkyl,
fluorinatedC₁-₄alkyl, C₁-₄alkoxy, nitro, amino, (C₁-₄alkyl)amino, di(C₁-₄alkyl)amino,
20 C₁-₄alkylsulfonyl, amido, (C₁-₄alkyl)amido, di(C₁-₄alkyl)amido,
sulfonyl, aminosulfonyl, (C₁-₄alkyl)aminosulfonyl, di(C₁-₄alkyl)aminosulfonyl or
triphenylmethyl;

provided that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X is CH₂,

(A)

is phenyl, b is 0, c is 0 and m is 0, then R⁶ is selected from the group
25 consisting of partially unsaturated carbocyclyl, C₃-₈cycloalkyl, heteroaryl,
heterocycloalkyl, benzyloxyphenyl and substituted aryl;
wherein the aryl, partially unsaturated carbocyclyl, C₃-₈cycloalkyl,
heteroaryl or heterocycloalkyl group is optionally substituted with one to four
substituents independently selected from halogen, C₁-₆alkyl, halogenated C₁-₆alkyl,
30 C₁-₆alkoxy, nitro, amino, (C₁-₆alkyl)amino, di(C₁-₆alkyl)amino, C₁-₆alkyl,

$\text{C}_1\text{-}\text{C}_6$ alkylsulfonyl, amido, $(\text{C}_1\text{-}\text{C}_6$ alkyl)amido, di($\text{C}_1\text{-}\text{C}_6$ alkyl)amido, sulfonyl, aminosulfonyl, $(\text{C}_1\text{-}\text{C}_6$ alkyl)aminosulfonyl, di($\text{C}_1\text{-}\text{C}_6$ alkyl)aminosulfonyl or triphenylmethyl;

provided further that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X

5 is $\text{C}_1\text{-}\text{C}_3$ alkyl,  is phenyl, b is 0, c is 0 and m is 0, then R^6 is not substituted thiazolyl; wherein the substituent on the thiazolyl is selected from amino, $\text{C}_1\text{-}\text{C}_4$ alkylamino, di($\text{C}_1\text{-}\text{C}_4$ alkyl)amino or nitro;

provided further that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X

10 is CH_2 , b is 0, c is 0 and m is 0, and R^6 is phenyl, then  is not imidazolyl or pyrrolyl;

and pharmaceutically acceptable salts thereof.

3. A compound as in Claim 2 wherein

15 R^1 is selected from the group consisting of $\text{C}_1\text{-}\text{C}_4$ alkyl, aryl and aralkyl; wherein the aryl group is optionally substituted with one to three substituent independently selected from halogen, $\text{C}_1\text{-}\text{C}_4$ alkyl, $\text{C}_1\text{-}\text{C}_4$ alkoxy, trifluoromethyl and $\text{C}_5\text{-}\text{C}_6$ cycloalkyl;

20 R^2 is selected from the group consisting of hydrogen, $\text{C}_1\text{-}\text{C}_4$ alkyl, hydroxy $\text{C}_1\text{-}\text{C}_4$ alkyl, cyano $\text{C}_1\text{-}\text{C}_4$ alkyl, amino $\text{C}_1\text{-}\text{C}_4$ alkyl, $\text{C}_1\text{-}\text{C}_4$ alkylamino $\text{C}_1\text{-}\text{C}_4$ alkyl, di($\text{C}_1\text{-}\text{C}_4$ alkyl)amino $\text{C}_1\text{-}\text{C}_4$ alkyl, aminocarbonyl $\text{C}_1\text{-}\text{C}_4$ alkyl, carboxy $\text{C}_1\text{-}\text{C}_4$ alkyl, $\text{C}_1\text{-}\text{C}_4$ alkoxycarbonyl $\text{C}_1\text{-}\text{C}_4$ alkyl, phthalimidoylethyl and $\text{C}_1\text{-}\text{C}_4$ alkoxycarbonyl-oxazolyl $\text{C}_1\text{-}\text{C}_4$ alkyl;

a is an integer from 0 to 1;

R^3 is selected from the group consisting of $\text{C}_1\text{-}\text{C}_4$ alkyl;

25 n is 1;

X is selected from the group consisting of $\text{C}_1\text{-}\text{C}_4$ alkyl and $\text{C}_2\text{-}\text{C}_4$ alkyl-O;

wherein X is $\text{C}_2\text{-}\text{C}_4$ alkyl-O, the X group is incorporated into the molecule such that the $\text{C}_2\text{-}\text{C}_4$ alkyl portion is bound directly to the piperidine portion of the molecule;



is selected from the group consisting of phenyl and heteroaryl;

b is 0;

c is an integer from 0 to 2;

R^5 is selected from the group consisting of halogen, fluorinated C_{1-4} alkyl

5 and C_{1-4} alkyl;

m is an integer from 0 to 1;

Y is selected from the group consisting of O, C_{1-4} alkyl-O, C_{2-4} alkenyl and C_{1-4} alkyl;

R^6 is selected from the group consisting of aryl, partially unsaturated

10 carbocyclyl, heteroaryl, heterocycloalkyl and benzoyloxyphenyl;

wherein the aryl, heteroaryl or heterocycloalkyl is optionally substituted with one to two substituents independently selected from halogen, acetyl, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl, amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, cyano, nitro, oxo, t-butoxycarbonyl or triphenylmethyl;

15 provided that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X is CH_2 ,



is phenyl, b is 0, c is 0 and m is 0, then R^6 is selected from the group consisting of partially unsaturated carbocyclyl, C_{3-8} cycloalkyl, heteroaryl, heterocycloalkyl, benzoyloxyphenyl and substituted aryl;

wherein the aryl, heteroaryl or heterocycloalkyl is optionally substituted

20 with one to two substituents independently selected from halogen, acetyl,

hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl, amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, cyano, nitro, oxo, t-butoxycarbonyl or triphenylmethyl;

provided further that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X



is C_{1-3} alkyl, is phenyl, b is 0, c is 0 and m is 0, then R^6 is not

25 substituted thiazolyl; wherein the substituent on the thiazolyl is selected from amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino or nitro;

provided further that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X



is CH₂, b is 0, c is 0 and m is 0, and R⁶ is phenyl, then
or pyrrolyl;

and pharmaceutically acceptable salts thereof.

5

4. A compound as in Claim 3 wherein

R¹ is selected from the group consisting of n-propyl, phenyl, 4-fluorophenyl, 3-bromophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 4-methylphenyl, 4-methoxyphenyl, 4-cyclopentylphenyl, 4-chloro-3-methylphenyl,

10 4-fluoro-3,5-dimethylphenyl and benzyl;

R² is selected from the group consisting of hydrogen, methyl, cyanomethyl, 2-hydroxyethyl, aminoethyl, dimethylaminoethyl, diethylaminoethyl, aminocarbonylmethyl, carboxymethyl, methoxycarbonylmethyl, phthalimidoylethyl and 4-methoxycarbonyl-5-

15 oxazolylmethyl;

a is an integer from 0 to 1;

R³ is methyl;

n is 1;

X is selected from the group consisting of CH₂, and CH₂CH₂,

20 CH₂CH₂CH₂, CH₂CH₂CH₂CH₂ and CH₂CH₂-O;



is selected from the group consisting of phenyl, furyl, thienyl, pyridyl and pyrazolyl;

b is 0;

c is an integer from 0 to 2;

25 R⁵ is selected from the group consisting of fluoro, chloro, trifluoromethyl and methyl;

m is an integer from 0 to 1;

Y is selected from the group consisting of O, CH₂-O, CH=CH and CH₂;

30 R⁶ is selected from the group consisting of 3-methylphenyl, 4-methylphenyl, 3,5-dichlorophenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 3-

pyridyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 1-naphthyl, 2-naphthyl, 2-(1-Boc-pyrrolyl), 1-(1,2,3,4-tetrahydronaphthyl), phenyl, 4-dimethylaminophenyl, 4-pyridyl, 3-quinolinyl, 2-benzothienyl, 2-benzofuryl, 5-indolyl, 2-thiazolyl, 5-chloro-2-thienyl, 5-acetyl-2-thienyl, 5-methyl-2-thienyl, 5-
5 cyano-2-thienyl, 4-methyl-2-thienyl, 3,5-dimethyl-4-isoxazolyl, 3-pyridyl, 4-chlorophenyl, 1-(5,6,7,8-tetrahydronaphthyl), 4-hydroxy, 1-piperidinyl, 1-(1,2,3,4-tetrahydroquinolinyl), 2-(1,2,3,4-tetrahydroisoquinolinyl), 1-pyrrolidinyl, 1-phthalimidoyl, 1-imidazolyl, 3-imidazolyl, 1-triphenylmethyl-3-imidazolyl, 1-(2-piperidinyl), 3-chlorophenyl, 4-nitrophenyl, 4-bromophenyl, 4-chlorophenyl and
10 benzyloxyphenyl;

provided that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X is CH₂,



is phenyl, b is 0, c is 0 and m is 0, then R⁶ is not phenyl;
and pharmaceutically acceptable salts thereof.

15 5. A compound as in Claim 4 wherein

R¹ is selected from the group consisting of phenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 4-methylphenyl, 3-bromophenyl, 3-chlorophenyl, 4-chloro-3-methylphenyl and 4-fluoro-3,5-dimethylphenyl;

R² is selected from the group consisting of hydrogen, methyl,

20 cyanomethyl, 2-hydroxyethyl, aminoethyl, dimethylaminoethyl, diethylaminoethyl, aminocarbonylmethyl, carboxymethyl, methoxycarbonylmethyl and 4-methoxycarbonyl-5-oxazolylmethyl;

X is selected from the group consisting of CH₂, and CH₂CH₂,

CH₂CH₂CH₂ and CH₂CH₂CH₂CH₂;

25 c is an integer from 0 to 1;

R⁵ is selected from the group consisting of fluoro, trimethylphenyl and methyl;



is selected from the group consisting of phenyl, furyl, thienyl and pyrazolyl;

30 Y is selected from the group consisting of O, CH₂-O and CH=CH;

R^6 is selected from the group consisting of 4-methylphenyl, 3,5-dichlorophenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 3-pyridyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 1-naphthyl, 2-naphthyl, 1-(1,2,3,4-tetrahydronaphthyl), phenyl, 2-thiazolyl, 5-chloro-2-thienyl, 5-methyl-2-thienyl, 5 4-methyl-2-thienyl, 3,5-dimethyl-4-isoxazolyl, 4-chlorophenyl, 4-bromophenyl and 4-chlorophenyl;

provided that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X is CH_2 ,



is phenyl, b is 0, c is 0 and m is 0, then R^6 is not phenyl; and pharmaceutically acceptable salts thereof.

10

6. A compound as in Claim 5 wherein

R^1 is selected from the group consisting of phenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 4-methylphenyl, 3-bromophenyl and 4-chloro-3-methylphenyl;

15 X is selected from the group consisting of CH_2 , and CH_2CH_2 and $CH_2CH_2CH_2$;



is selected from the group consisting of phenyl and thienyl;

R^5 is fluoro;

m is an integer from 0 to 1;

20 Y is O;

R^6 is selected from the group consisting of phenyl, 3-pyridyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 2-thiazolyl and 4-methyl-2-thienyl;

provided that when a is 0, R^1 is phenyl, R^2 is hydrogen, n is 1, X is CH_2 ,



is phenyl, b is 0, c is 0 and m is 0, then R^6 is not phenyl;

25 and pharmaceutically acceptable salts thereof.

7. A compound as in Claim 6 wherein

R^1 is selected from the group consisting of phenyl and 4-fluorophenyl;

R^2 is selected from the group consisting of hydrogen, methyl, cyanomethyl, 2-hydroxyethyl, dimethylaminoethyl, aminocarbonylmethyl and methoxycarbonylmethyl;



is phenyl;

5 R^6 is selected from the group consisting of 2-furyl, 2-thienyl and 3-thienyl;

and pharmaceutically acceptable salts thereof.

8. A compound as in Claim 1 wherein

10 R^1 is selected from the group consisting of hydrogen, C₁₋₆alkyl and aryl; wherein the aryl group is optionally substituted with one to four substituents independently selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl, di(C₁₋₆alkyl)aminosulfonyl or C₃₋₈cycloalkyl;

15 R^2 is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, hydroxyaminoC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, aryl, C₃₋₈cycloalkyl, partially unsaturated carbocyclyl, heteroaryl, heterocycloalkyl, C₁₋₆aralkyl, carbocyclylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocycloalkylC₁₋₆alkyl and phthalimidoylC₁₋₆alkyl;

20 wherein the alkyl group is optionally substituted with one to two substituents independently selected from hydroxy, carboxy, cyano, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, hydroxyC₁₋₆alkylamino, aminoC₁₋₆alkylamino, C₁₋₆alkylaminoC₁₋₆alkylamino or di(C₁₋₆alkyl)aminoC₁₋₆alkylamino,

25 wherein the aryl, cycloalkyl, carbocyclyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl or di(C₁₋₆alkyl)aminosulfonyl;

a is an integer from 0 to 2;

R^3 is selected from the group consisting of C_{1-4} alkyl and hydroxy C_{1-4} alkyl;

n is an integer from 0 to 1;

5 X is selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-4} alkyl-O and C_{2-4} alkyl-S;
wherein the alkyl group is optionally substituted with one to two substituents independently selected from fluoro, C_{1-6} alkyl, fluorinated C_{1-6} alkyl, C_{1-6} alkoxy, nitro, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfonyl, 10 amido, (C_{1-6} alkyl)amido, di(C_{1-6} alkyl)amido, sulfonyl, aminosulfonyl, (C_{1-6} alkyl)aminosulfonyl or di(C_{1-6} alkyl)aminosulfonyl;
and wherein X is C_{2-4} alkyl-O or C_{2-4} alkyl-S, the X group is incorporated into the molecule such that the C_{2-4} alkyl is bound directly to the piperidine portion of the molecule;

15 A is selected from the group consisting of phenyl, a five membered heteroaryl and a six membered heteroaryl;

b is an integer from 0 to 1;

R^4 is selected from the group consisting of aryl, C_{3-8} cycloalkyl, partially unsaturated carbocyclyl, heteroaryl and heterocycloalkyl;

20 c is an integer from 0 to 3;

R^5 is selected from the group consisting of halogen, C_{1-6} alkyl, halogenated C_{1-6} alkyl, C_{1-6} alkoxy, nitro, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfonyl, amido, (C_{1-6} alkyl)amido, di(C_{1-6} alkyl)amido, sulfonyl, aminosulfonyl, (C_{1-6} alkyl)aminosulfonyl or di(C_{1-6} alkyl)aminosulfonyl;

25 m is an integer from 0 to 1;

Y is selected from the group consisting of C_{1-4} alkyl, C_{2-4} alkenyl, O, S, NH, N(C_{1-4} alkyl), C_{1-6} alkyl-O, C_{1-6} alkyl-S, O- C_{1-6} alkyl and S- C_{1-6} alkyl-S;

R^6 is selected from the group consisting of aryl, partially unsaturated carbocyclyl, C_{3-8} cycloalkyl, heteroaryl, heterocycloalkyl and benzoyloxyphenyl;

30 wherein the aryl, partially unsaturated carbocyclyl, C_{3-8} cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four

substituents independently selected from halogen, hydroxy, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl or di(C₁₋₆alkyl)aminosulfonyl;

5 provided that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X is CH₂,



(A) is phenyl, b is 0, c is 0 and m is 0, then R⁶ is selected from the group consisting of partially unsaturated carbocyclyl, C₃₋₈cycloalkyl, heteroaryl, heterocycloalkyl and substituted aryl;

wherein the aryl, partially unsaturated carbocyclyl, C₃₋₈cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to four substituents independently selected from halogen, C₁₋₆alkyl, halogenated C₁₋₆alkyl, C₁₋₆alkoxy, nitro, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, C₁₋₆alkylsulfonyl, amido, (C₁₋₆alkyl)amido, di(C₁₋₆alkyl)amido, sulfonyl, aminosulfonyl, (C₁₋₆alkyl)aminosulfonyl or di(C₁₋₆alkyl)aminosulfonyl;

10 provided further that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X



is C₁₋₃alkyl, (A) is phenyl, b is 0, c is 0 and m is 0, then R⁶ is not substituted thiazolyl; wherein the substituent on the thiazolyl is selected from amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino or nitro;

provided further that when a is 0, R¹ is phenyl, R² is hydrogen, n is 1, X

20 is CH₂, b is 0, c is 0 and m is 0, and R⁶ is phenyl, then (A) is not imidazolyl or pyrrolyl;

and pharmaceutically acceptable salts thereof.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.

25

10. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

11. A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 5 12. A method of treating a disorder mediated by the ORL-1 receptor, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
- 10 13. The method of Claim 12, wherein the disorder mediated by the ORL-1 receptor is selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition.
- 15 14. A method of treating a disorder mediated by the ORL-1 receptor, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 9.
- 20 15. A method of treating a condition selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
- 25 16. A method of treating a condition selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 9.
- 30 17. The use of a compound as in Claim 1 for the preparation of a medicament for the treatment of (a) anxiety, (b) depression, (c) substance abuse, (d) neuropathic pain, (e) acute pain, (f) migraine, (g) asthma, (h) cough or for (i) improved cognition, in a subject in need thereof.

INTERNATIONAL SEARCH REPORT

Inte il Application No
PCT/US 02/10736

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D471/10 A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 07050 A (SCHERING CORP) 1 February 2001 (2001-02-01) page 47-59; table 6 claim 2 ---	1-17
X	WO 00 06545 A (SCHERING CORP) 10 February 2000 (2000-02-10) page 41-53; table 6 claims 1,11 ---	1-17
Y	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 09, 13 October 2000 (2000-10-13) & JP 2000 169476 A (BANYU PHARMACEUT CO LTD), 20 June 2000 (2000-06-20) abstract ---	1-17 -/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 June 2002

Date of mailing of the international search report

15/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Samsam Bakhtiary, M

INTERNATIONAL SEARCH REPORT

Interr Application No

PCT/US 02/10736

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 997 464 A (PFIZER) 3 May 2000 (2000-05-03) page 1, line 1-25 claim 1 ---	1-17
Y	HENDERSON G ET AL: "The orphan opioid receptor and its endogenous ligand - nociceptin/orphanin FQ" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 8, 1 August 1997 (1997-08-01), pages 293-300, XP004085920 ISSN: 0165-6147 the whole document ---	1-17
Y	EP 0 856 514 A (HOFFMANN LA ROCHE) 5 August 1998 (1998-08-05) claims 1,16 ---	1-17
P,X	WO 01 39723 A (EURO CELTIQUE SA ;KYLE DONALD (US); GOEHRING R RICHARD (US)) 7 June 2001 (2001-06-07) claims 1,15 ---	1-17
P,X	WO 01 36418 A (PETTERSSON INGRID ;HOHLWEG ROLF (DK); NOVO NORDISK AS (DK); WATSON) 25 May 2001 (2001-05-25) claims 1,9 ---	1-11
A	SELWAY, CHRISTOPHER N. ET AL: "Parallel-compound synthesis: methodology for accelerating drug discovery" BIOORG. MED. CHEM. (1996), 4(5), 645-654 , XP002203777 page 647; table 1 compound 7 ---	1-11
A	THURKAUF, ANDREW ET AL: "2-Phenyl-4-(aminomethyl)imidazoles as Potential Antipsychotic Agents. Synthesis and Dopamine D2 Receptor Binding" J. MED. CHEM. (1995), 38(12), 2251-5 , XP002203778 page 2253; example 15 ---	1-11

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 12-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT – Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

I... International application No.
PCT/US 02/10736

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inter Application No
PCT/US 02/10736

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0107050	A	01-02-2001	US	6262066 B1		17-07-2001
			AU	2629800 A		13-02-2001
			BR	0012801 A		07-05-2002
			EP	1200087 A1		02-05-2002
			NO	20020392 A		25-03-2002
			WO	0107050 A1		01-02-2001
			US	2001011092 A1		02-08-2001

WO 0006545	A	10-02-2000	AU	5205699 A		21-02-2000
			BR	9912495 A		02-05-2001
			CN	1311777 T		05-09-2001
			EP	1100781 A1		23-05-2001
			NO	20010467 A		26-03-2001
			PL	345671 A1		02-01-2002
			SK	962001 A3		10-07-2001
			TR	200100241 T2		21-06-2001
			WO	0006545 A1		10-02-2000

JP 2000169476	A	20-06-2000	NONE			

EP 0997464	A	03-05-2000	BR	9904962 A		08-08-2000
			EP	0997464 A1		03-05-2000
			JP	2000128879 A		09-05-2000

EP 0856514	A	05-08-1998	EP	0856514 A1		05-08-1998
			SI	856514 T1		31-08-2001
			AT	202105 T		15-06-2001
			AU	730147 B2		01-03-2001
			AU	5280998 A		06-08-1998
			BR	9800524 A		14-03-2000
			CA	2226058 A1		30-07-1998
			CN	1191862 A		02-09-1998
			CZ	9800273 A3		12-08-1998
			DE	69800896 D1		19-07-2001
			DE	69800896 T2		28-03-2002
			DK	856514 T3		17-09-2001
			ES	2158622 T3		01-09-2001
			HR	980043 A1		31-12-1998
			HU	9800138 A2		28-09-1998
			IL	123036 A		06-12-2000
			JP	10212290 A		11-08-1998
			KR	274107 B1		15-12-2000
			NO	980332 A		31-07-1998
			NZ	329627 A		29-11-1999
			PL	324571 A1		03-08-1998
			PT	856514 T		31-10-2001
			SG	71077 A1		21-03-2000
			TR	9800085 A2		21-08-1998
			TW	457238 B		01-10-2001
			US	6071925 A		06-06-2000
			ZA	9800570 A		30-07-1998

WO 0139723	A	07-06-2001	AU	1948601 A		12-06-2001
			WO	0139723 A2		07-06-2001
			US	2001041711 A1		15-11-2001

WO 0136418	A	25-05-2001	AU	1382901 A		30-05-2001
			WO	0136418 A1		25-05-2001